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Allergic asthma is a leading cause of morbidity in industrialized nations and results from lack of
immunologic tolerance to environmental antigens. Understanding the factors that contribute to immune
tolerance is critical for the development of improved therapeutic strategies for asthma. Although much
has been gained from studying ovalbumin (OVA)-induced mouse models of allergic airway disease
(AAD), OVA is far less immunologically complex than most human-relevant antigens. House dust mite
(HDM) is the most common cause of asthma worldwide. In a novel murine model of AAD, short-term (2
weeks) and intermediate-term (5 weeks) intranasal HDM exposure resulted in classic hallmarks of
asthma, including airway eosinophilia and airway hyper-reactivity (AHR). Intriguingly, long-term (11
weeks) HDM instillation resulted in suppression of Th2-mediated disease processes, providing the first
evidence of its kind that immunologic tolerance can develop with continuous exposure to a humanrelevant allergen. Moreover, HDM-induced tolerance resulted in suppression of disease despite persistent
lung inflammation rather than complete resolution of inflammation, which may be more clinically
representative of the processes involved with tolerance development in humans. While long-term
exposure to both OVA and HDM was associated with increased numbers of local Foxp3+ regulatory T
cells (Tregs), only long-term HDM exposure resulted in upregulation of IL-10 production by lung alveolar
macrophages (AM). These AMs were found to be capable of inducing Tregs, suggesting that they may
play an important role in the suppression of HDM-induced asthma. We believe that this macrophage
population may be exploitable for the development of enhanced immunotherapeutic strategies for asthma.
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CHAPTER 1
INTRODUCTION

I.

Allergic asthma: a global issue of epidemic proportion

“He was just starting to recover,
to recognize his comrades round him. He’d stopped
gasping and sweating, for aegis-bearing Zeus had revived his mind.”
-

The Iliad, book XV, line 290

Descriptions of the condition known as asthma have been floating around since the eighth century
B.C., when the term was first used in reference to Hector’s attempt to catch his breath post battle. The word
‘asthma’ has evolved quite a bit since it was originally described by Homer, who simply meant it to refer
to the symptom of dyspnea (difficulty breathing) rather than the disease. Yet it is no wonder that the
condition we know as modern-day asthma is rooted in the Greek language, having stemmed from the verb
‘aazein’ (to pant or exhale with an open mouth).
Asthma is a chronic inflammatory disorder of the airways that is characterized by recurrent
symptoms of coughing, wheezing, dyspnea, and chest tightness. It occurs in people of all ages, races, and
sexes in every nation in the world. Diagnosis is typically based on a mixture of history and clinical features
(respiratory symptoms) with support from objective findings, including evidence of reversible airflow
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obstruction (i.e. positive responses to bronchodilators). Nevertheless, definitions of asthma type and
severity can be quite variable, as no gold standard test is currently available to confirm or rule out the
diagnosis.

a. Epidemiology

Although asthma can come in many forms, the most common type is allergic asthma, accounting
for greater than 60% of all cases. The prevalence of asthma is extremely high in the Western world.
Approximately 8% of individuals in the United States are afflicted by this condition, though frequency may
be higher in specific demographic populations (smokers, urbanites, non-Hispanic blacks, children, etc.)1.
Prevalence of asthma across other nations varies widely, but this gap is indeed narrowing due to rising
prevalence in low and middle income countries. It is currently estimated that 300 million people worldwide
suffer from this condition. In addition, a quarter of a million deaths occur annually as a direct result of
asthma, many of which are entirely avoidable. Yet the biggest concern is that the incidence of asthma,
which is already high, continues to grow year by year. The total number of people in the United States with
asthma has increased by 2.9% annually, from 20.3 million (one in fourteen people) in 2001 to 25.7 million
(one in twelve people; 27% children) in 20102. By 2025, it is estimated that the number of asthmatics
worldwide will increase by 100 million people1. It is clear that asthma is a global health problem that will
soon reach epidemic proportions.

b. Economic and social burden

Although risk of premature death from asthma is relatively low, asthma is associated with
tremendous morbidity. It imposes a high frequency of health care utilization and lost productivity at work
The

term ‘asthma’ will be used to refer to ‘allergic asthma’ throughout the remainder of the text
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or school. A recent report suggested that approximately half of all individuals with asthma suffer from at
least one asthma attack† annually. As a result, asthma is a major cause of hospitalization in adults and the
third leading cause of hospitalization in persons under 18 years of age 3. Asthma attacks send 1.8 million
victims to the emergency room annually4 and generate 50% of the approximately $60 billion annual heath
care cost for asthma. Asthma also accounts for roughly 1% (14.2 million) of all annual ambulatory visits in
the United States. It has gained a reputation for being one of the leading causes of work and school
absenteeism and only continues to get worse. Unfortunately, the diagnosis of asthma is so common that
these repercussions have been both accepted and trivialized by the general public.
If there is any doubt regarding the severity of the “asthma epidemic”, one need only consider the
heavy economic burden of this disease. In 2009, annual expenditures per asthma patient totaled $3,300 in
direct health care costs and indirect expenses (i.e. lost productivity from missed school and work days)5.
On the whole, yearly direct medical and indirect costs of asthma are estimated to be about $56 billion,
accounting for over 1% of the annual $3.8 trillion health care expenditure. The often chronic nature of
asthma further contributes to the tremendous economic consequences of this disease. Unfortunately, the
increasing prevalence of asthma and rising costs of health care signify that this problem could become much
worse without proper intervention.

II.

Pathophysiology and mechanisms of disease

a. The intolerant immune system

In order to understand the causes of asthma, one must first acknowledge the key function of the
immune system, which serves to protect the host against pathogenic invaders (bacteria, viruses, etc.)

†

Potentially life-threatening situation in which the airways become swollen, inflamed, and constricted (i.e.
reversibly obstructed)
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through a variety of defense mechanisms we have loosely termed ‘inflammation’. Inflammation describes
a complex biological response to harmful stimuli that involves a specialized set of cells (leukocytes) and
molecular mediators. While inflammation is extremely effective at ridding the body of harmful
organisms, it often takes casualties in the form of damage to host cells and tissues, thus rendering it
undesirable unless absolutely necessary. In an effort to prevent immune reactions against non-threatening
substances, the immune system has adopted a rather unique set of mechanisms to discriminate against self
and non-self, a concept referred to as immunologic tolerance. Immunologic tolerance, which describes the
state of non-reactivity or unresponsiveness against an antigen (Ag), is an extremely important
phenomenon for maintaining homeostasis. Not only does it hinder the immune system from reacting
against self Ags, it is particularly important for preventing reactions against environmental Ags, which are
both ubiquitous and innocuous to the body. The key players involved in tolerance will be further
discussed in section IId and IIe.
Although every individual is exposed to a ubiquitous array of allergens over the course of his/her
lifetime, only a relatively small percentage proceed to develop allergic reactions. Atopy refers to the
predisposition towards development of exaggerated immune responses against innocuous, environmental
allergens. Thus, the pathophysiology of asthma and other atopic disorders may be best accepted as an
intrinsic immune defect that manifests when exposed to specific environmental conditions. In the same
manner that reactions against self Ags can lead to the development of autoimmune disease, lack of tolerance
against environmental Ags (e.g. house dust mite [HDM], pet dander, mold, smoke) precipitates
development of atopic disorders. Atopic reactions in the lung are responsible for symptoms of allergic
asthma.
In light of this concept, several hypotheses have been proposed to account for this rising incidence
of asthma, many of which relate to negative changes within our global environment (e.g. enhanced air
pollution) over the past few decades. However, the best-known theory is, perhaps, the “hygiene hypothesis”,
which attributes increased asthma incidence (as well as incidence of other atopic disorders) to a variety of
lifestyle changes that have reduced infection rates in developed nations6. Prolonged exposure to bacterial
4

products has been shown to be protective against development of asthma and atopy through chronic
stimulation of Toll-like receptors (TLRs) on innate immune cells. Although the specific immunological
mechanism that explains why reduced TLR stimulation during early childhood results in a heightened
immune responses to allergens is still a matter of controversy, some have suggested that lower microbial
burden reduces the activity of the regulatory immune cells that mediate proper tolerance development.

b. Type I hypersensitivity reactions: early-phase response to allergens and production of IgE

The type I hypersensitivity response is believed to underlie the majority of allergic reactions,
including asthma. These responses are typically initiated upon sensitization to an allergen in a susceptible
individual.
Sensitization phase
Airborne allergens are typically small yet complex proteins that are carried on dry particles (e.g.
pollen, dust mite feces). When these particles make contact with the upper respiratory tract and/or
airways, allergenic peptides are eluted off their carrier compounds and then diffuse into the mucosa. This
action is facilitated by the proteolytic activity of many human allergens, which damages tight junctions of
epithelial cells lining the airway and promotes barrier dysfunction7. In response to TLR signaling from
allergens (e.g. HDM signaling of TLR4 on epithelial cells)8, damaged epithelial cells release interleukin25 (IL-25), IL-33, and thymic stromal lymphopoeitin (TSLP), the latter of which is crucial for the
activation of dendritic cells (DCs) and aids in programming DCs to become Type 2 helper (Th2) cell
inducers9,10. IL-25 and IL-33, on the other hand, are critical for the activation of type 2 innate lymphoid
cells (ILC2), which immediately respond by secreting a host of Th2 cytokines. In addition, IL-25
stimulates the accumulation of type 2 multipotent progenitor (MPPtype2) cells in the mucosa that give rise
to cells of the monocyte-macrophage and granulocyte lineages capable of promoting type 2
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inflammation11. These actions ensure an immediate response to epithelial cell damage even prior to the
activation of Th2 cells.
Following damage to the epithelial surface, allergens gain access to an extensive submucosal
dendritic cell (DC) network. In addition, β-glucan-rich motifs on specific allergens (e.g. HDM) can
interact with dectin-1 on bronchial epithelial cells and stimulate their production of CCL20, a chemokine
that is vital for attraction of immature lung DCs12. Myeloid DCs pick up and process the Ag, after which
time they undergo an extensive maturation process. During this time, DCs lose their intrinsic ability to
process Ag but acquire full Ag-presentation capacity (e.g. expression of co-stimulatory molecules and T
cell chemokines)13. MHCII-loaded DCs then migrate from the mucosa to the T-cell rich areas of the hilar
lymph node (HLN), where they await the arrival of Ag-specific T cells. Upon encountering these
cells, DCs subsequently prime them towards a Th2 phenotype via expression of Th2-instructive cell
surface signals (e.g. Notch ligand jagged-2, c-Kit, OX40L)14. However, it is important to note that DCs
have not been found to be an important source of IL-4, the hallmark Th2 polarizing cytokine.
Interestingly, it has been shown that basophils are an important source of IL-4 and may serve as a bona
fide APCs that can provide peptide-MHC, costimulation, and Th2-polarizing cytokines even in the
absence of DCs15,16. As a result, many have speculated that DCs may have a redundant role in the process
of allergen sensitization; however, their necessity in priming Th2 cell responses is still hotly debated.
Th2 cells can influence B cell class switching to IgE-secreting plasma cells. This process requires two
signals: 1) STAT-6-mediated transcription at the IgE isotype-specific switch region (influenced by IL-4
or IL-13) and 2) ligation of CD40 on B cells with CD40L on T cells. At the initiation of class switching,
T cells provide both signals; however, basophils have been suggested to play a role in polyclonal
amplification of IgE17. Following initiation of its production, IgE then binds to the surface of mast cells,
basophils, and eosinophils via interactions of its constant region with the high-affinity FcεR1. At this
point, the sensitization phase has been completed.
Lung-draining

lymph node
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c. Disease progression:

Allergen challenge: early phase
Once the triggering allergen is re-introduced to the host, it is bound by IgE on the surface of mast
cells, which leads to cross-linking of FcεRI. This cross-linking results in subsequent recruitment of Syk
kinase, which stimulates a number of downstream signaling events associated with activation of mast
cells, basophils, and eosinophils. Mast cells, in particular, may release pre-formed mediators such as
histamine, which allows for rapid initiation of an inflammatory reaction in response to Fc receptor
triggering18. Histamine is a major contributor to the phenotype associated with allergic asthma. Not only
can it bind to H1 receptors on airway smooth muscle cells and cause bronchoconstriction, it also
stimulates widespread vasodilation, leading to mucosal edema. In addition, mast cells can rapidly
synthesize molecules such as phospholipids (e.g. prostaglandins and leukotrienes), the latter of which can
promote bronchoconstriction, enhanced permeability, and chemotaxis of neutrophils. Mast cells are also
involved in the production of chemokines that recruit T cells (RANTES, TARC), macrophages (MCP-1),
and eosinophils (eotaxin) to the lung tissue. Mast cell and basophil degranulation in response to
crosslinking of the IgE-FcεRI complexes by allergen constitutes the immediate phase of the allergic
reaction.
Late phase
IgE may also bind to FcεRI on the surface of DCs and monocytes as well as to the low-affinity IgE
receptor (FcεRII; CD23) on the surface of B cells. This process facilitates allergen uptake by these APCs,
where they are subsequently presented to allergen-specific CD4+ T cells. CD4+ T cells drive the late
phase of the allergic reaction. In response to subsequent allergen exposure, newly polarized Th2 cells
respond by secreting cytokines and chemokines that augment the allergic response. These include
molecules such as IL-4, IL-13 and IL-5, all of which have been shown to be increased in the BAL and
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serum of allergic individuals19. IL-4 is, perhaps, the most classic and important Th2 cytokine in the
development of asthma. One of its essential biological activities involves the Stat-6-mediated conversion
of naïve T cells into Th2 effector cells that are capable of initiating asthmatic responses. IL-4 is also a
critical player in the process of B cell immunoglobulin isotype switching from the IgM subclass to IgE,
another important function in the pathogenesis of asthma. Aberrant production of IL-4 or
hyperresponsiveness to this cytokine may contribute to the pathology of this disease; asthma has indeed
been genetically linked to polymorphisms in the genes encoding the IL-4 receptor, Stat-6, and BCL6, the
latter of which counteracts the effects of Stat-620. Studies in mice have demonstrated that neutralizing the
effects of IL-4 before allergen sensitization inhibits the development of allergen-specific IgE and
attenuates eosophil influx in an IL-5-dependent manner21. Interestingly, the same treatment given after
priming but before allergen challenge was not effective at preventing allergic inflammation. Thus, while
IL-4 is likely important for committing cells to the Th2 lineage, it is not as essential as other Th2
cytokines for the effector phase of the asthmatic response.
Because of its structural similarity to IL-4 and sharing of receptor components, IL-13 was
hypothesized to play a role in the development of allergic responses. Studies have demonstrated that IL13 is consistently overexpressed in the lungs of human asthmatics and that polymorphisms in this gene
can contribute to susceptibility and pathogenesis of asthma22. Unlike IL-4, IL-13 does not have a role in
the differentiation of Th2 cells; however, it has been shown to be important for the effector arm of the
allergic immune response. When IL-13 but not IL-4 was blocked in allergen-challenged mice via
administration of a soluble form of the IL-13Rα2 chain, results demonstrated a reversal of mucus
production and airway hyperreactivity (AHR), two hallmark features of asthma that lead to cardinal signs
of wheezing and dyspnea23,24. Airway plugging through hypersecretion of mucus is one of the primary
reasons for dyspnea in asthmatic patients (i.e. due to airway obstruction). The other reason can be
attributed to the hyperresponsiveness of smooth muscle to bronchoconstricting agents, leading to the
phenomenon of AHR (increased sensitivity of the airways to the phenomenon of bronchospasm upon
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interaction with an inhaled constrictor agonist). Further evidence of IL-13’s role in asthma was
demonstrated when acute administration of this cytokine was sufficient to produce AHR, eosinophilia,
and mucus cell hyperplasia in naïve and RAG-deficient animals23,24. However, despite the importance of
IL-13 in the effector phase of the asthmatic response, the exact mechanisms by which it induces AHR and
mucus hypersecretion remain unclear. One mechanism that may help to explain the precise role of IL-13
in disease pathogenesis is its ability to induce a host of chemokines that can selectively recruit various
leukocyte subtypes into the airways23. IL-5 is critical for the regulation of eosinophil development,
proliferation, survival, and activation25. Transgenic mice expressing constitutive IL-5 in all T cells
demonstrate severe and chronic eosinophilia, which can be observed in both the lungs and HLN26.
In addition to Th2 cells and mast cells, eosinophils have been classically considered to be a hallmark
cell of asthma. Under homeostatic conditions, eosinophils develop from CD34+ progenitors in the bone
marrow under the influence of IL-5, a cytokine which, as mentioned above, helps to promote their
activation and survival. Eosinophils then migrate from the bone marrow into the blood (1-3% of blood
leukocytes), and subsequently circulate through the lymphoid tissue and lung in low numbers. In response
to allergen challenge, a significantly greater proportion of eosinophils are recruited to the lung under the
influence of the chemokines produced by the airway epithelium, chemokine ligand 11 (CCL11; eotaxin-1)
and CCL2 (eotaxin-2), as well as the Th2 cytokine IL-1327. Once in the lung, eosinophils execute a
variety of functions, including secretion of preformed mediators (e.g. major basic protein, eosinophil
cationic protein, eosinophil peroxidase) that cause damage to the airways, synthesis and secretion of
leukotrienes, cytokine and chemokine production, and exacerbation of Th2 responses. Studies in
eosinophil-deficient PHIL mice exposed to OVA Ag have shown that AAD-associated histopathology
and AHR was reduced when compared to wild type (WT) mice28, suggesting that eosinophils have a
central role in the pathophysiology of asthma. Furthermore, intratracheal transfer of eosinophils into
OVA-treated IL-5-/- mice (in which eosinophils are severely lacking) resulted in restoration of mucus
hypersecretion, BAL Th2 cytokine levels, and AHR29. Recent studies from animal models of asthma have
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demonstrated that eosinophils may also play a significant role in the enhancement of Th2 responses by
acting as professional antigen presenting cells (APCs). After exposure to allergen, eosinophils upregulate
MHCII and levels of co-stimulatory molecules (CD40, CD80, CD86) and migrate to the local draining
lymph node of the lung, where they are capable of priming T cell responses30.
Note: Many additional cell types beyond Th2 cells and eosinophils are implicated in the pathogenesis
of asthma, including macrophages (discussed in Section IIe), DCs, lymphocytes, epithelial cells, NK cells,
neutrophils (particularly in severe asthma), and innate lymphoid cells. Although the contributions of these
cell types will not be specifically discussed in detail within this dissertation, the tremendous complexity
of asthma (and the hurdles we face to cure it; see Section III) are reflected in the myriad of cell types
involved in this disease and their overlapping functions.
Chronic disease
As a result of chronic inflammation in the lung, bronchial airways undergo significant remodeling
over time. Airway remodeling is a term that indicates changes to the composition, quantity, and
organization of the cellular components of the airway wall due to chronic injury and repair. These
structural alterations can contribute to the loss of lung function that is commonly seen in asthmatic
patients, and include airway wall thickening, epithelial injury/shedding, airway smooth muscle
hyperplasia/hypertrophy, goblet cell hyperplasia, and subepithelial fibrosis31. While increases in airway
smooth muscle mass and mucus hypersecretion can both exacerbate the airway obstruction and narrowing
that are classically associated with asthma, the pathophysiologic consequences of subepithelial fibrosis
are less clear. However, this process is typically irreversible and tends to correlate with the decline in
FEV1 that is characteristic of asthma32.
Unfortunately, the stimuli that contribute to airway remodeling are not well defined due to the limited
availability of lung biopsy specimens from patients with chronic asthma. However, TGF-β is thought to
have a substantial role in this process. TGF-β is produced by fibroblasts, eosinophils, macrophages, and
lymphocytes and is detected in high quantities in the BAL of asthmatic patients relative to control
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subjects33. Its levels often correlate with basement membrane thickness and overall disease severity.
Other cytokines that may be involved in the process of subepithelial fibrosis include GM-CSF34 and IL1335, the latter of which has been associated with upregulation of arginase-136. Some studies have
demonstrated that remodeling is unchanged or only mildly attenuated by the presence of steroid therapy37.
Curative therapies for asthma are required to prevent this deterioration in lung function over time.

d. Restoring homeostasis in the airways: The critical role of Regulatory T cells (Tregs)

Albeit a powerful tool for ridding the body of harmful pathogens, the immune system must refrain
from mounting reactions against self proteins and innocuous Ags, lest it unnecessarily damage host cells
and tissues (see Section IIa). This requires that the immune system have a regulatory arm to restrain itself
in the face of excessive inflammation. Of regulatory immune cells, none is more widely regarded or
studied than the regulatory T cell (Treg).
Discovery of Tregs
There is no doubt that the body has developed several important mechanisms for preventing
reactions against non-pathogenic Ags. Negative selection of self-reactive T cells in the thymus leads to
elimination of high-affinity T cell clones that recognize self, and engagement of TCRs by self proteins
can induce a state of anergy (unresponsiveness). Moreover, the two-signal hypothesis of T cell activation
requires that APCs deliver adequate co-stimulatory signals to T cells in addition to stimulation of the
TCR, many of which do not arise in the absence of strong inflammatory signals. Nevertheless, these
(central and peripheral) mechanisms of tolerance have been insufficient to counteract the threat of
immune-mediated pathology without the presence of a specialized subset of T cells acting in conjunction
to dampen the immune system. Initial evidence in support of the development of natural (thymicgenerated) T cells capable of performing this function came from early thymectomy experiments, which
effectively demonstrated that thymic removal between d2 and d4 of life resulted in T cell-mediated tissue
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damage38,39. However, this pathophysiological process was discouraged by the transfer of thymocytes or
splenocytes from euthymic adult mice, suggesting that a population of T cells generated in the thymus
around d3 of life is essential for prevention of autoimmune disease40,41. This early work culminated in the
eventual discovery of a CD4+ T cell subset expressing high amounts of CD25 (high-affinity IL-2 receptor
α-chain). These cells, termed Tregs, were proven to have a unique suppressive potential42. Unfortunately,
the utility of identifying Tregs on the basis of CD25 expression was limited by the fact that all activated T
cells upregulate this marker.
More insight into the biology of Tregs were facilitated by studies in mice with mutations in the
forkhead box P3 (Foxp3) transcription factor and in humans with IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked) syndrome. It appeared that both sets of subjects were
afflicted with a deadly, early-onset disorder involving both autoimmune and allergic components43. On
the basis of these observations, murine studies were conducted that revealed stable expression of Foxp3 in
naïve CD4+CD25+ T cells (Tregs) but not in naïve CD4+CD25- cells or in activated T cells44. Furthermore,
these cells were also shown to confer suppressor function on peripheral T cells45. Since this time, many
additional papers have demonstrated that Foxp3 is critical for Treg differentiation* and suppressor
function. It is also the most specific and widely accepted marker of the Treg lineage, particularly in mice†.
In addition to natural (thymic-derived) Tregs (nTregs), Foxp3+ Tregs can also be generated in the
periphery; these are known as inducible or adaptive Tregs (iTregs)46. Other inducible Treg subtypes
include Foxp3-IL-10+ TGF-β+ Tr1 cells and Foxp3-TGF-β+ Th3 cells. In addition to CD4+ T cells,
CD8+CD28-Foxp3+ T suppressor cells have also been described. The functions of Tr1 cells will be
discussed more in Section III; however, the remainder of this discussion will specifically focus on
mechanisms of Foxp3+ Tregs. In addition to their origin, Foxp3+ nTreg and iTreg subpopulation differ in
their phenotype, differentiation requirements (the former requires recombination-activating gene [RAG]),

*
†

In addition to Foxp3, IL-2 and TGF-β (and to a lesser extent, IL-7 and IL-15) are critical for Treg differentiation
In humans, Foxp3 is a less specific Treg marker as it can also be expressed on activated T cells
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and homing behavior47. It has also been reported that the two may have differential TCR repertoires;
nTregs may be more important for controlling autoantigen reactions (thus preventing autoimmunity),
while iTregs are more commonly generated in response to innocuous, environmental Ags46. However, this
opinion is rather controversial.
Importance of Tregs in asthma
In addition to prevention of autoimmune disorders, the phenotype of patients with IPEX
syndrome demonstrates that Tregs also play a critical role in the regulation of asthma and other allergic
diseases. Decreased Treg levels or defective Treg function has been associated with development of hyper
IgE syndrome, hypereosinophilia, and allergic airway inflammation in Foxp3 mutant mice48. It has been
theorized that the reason why only a select percentage of individuals develop asthma is because their
suppressive immune cells (i.e. Tregs) are either 1) decreased 2) defective or 3) overwhelmed49. Patients
with asthma who lack this tolerance have been shown to have decreased Tregs in their airways49,50, a
reduced ratio of Tregs to IL-4-secreting T cells, as well as decreased expression of Foxp3 in CD4+CD25hi
T cells51. In addition, studies have shown that CD4+CD25+ T cells from non-atopic donors suppress
proliferation and IL-5 production by their own, allergen-stimulated CD4+CD25– T cells to a greater degree
than CD4+CD25+ T cells from atopic donors, the latter of which show better suppressive capacity than
CD4+CD25+ T cells isolated from patients with hay fever during the pollen season52. This demonstrates
that Tregs from atopic and allergic individuals are indeed defective in some capacity. A similar reduction
in Foxp3 expression and Treg suppressive capacity was demonstrated in HDM-allergic children compared
to healthy controls, which was restored when anti-TNF-α was administered51. Interestingly, Hartl et al.
demonstrated that the frequency of Tregs and Foxp3 mRNA in the BAL correlate positively with FEV1 in
children with asthma, suggesting that Tregs (or a lack thereof) may play a critical role in reduction of
pulmonary function observed in asthmatic individuals (an effect that may be influenced by their
suppression of Th2 cytokines and chemokines)53. Moreover, successful treatment of asthma with
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corticosteroids (see Section IIIa) and allergen-specific immunotherapy (see Section IIIc) have both been
associated with increases in Tregs and improvements in inflammation and pulmonary function54.
The pivotal role of Tregs in maintaining immune tolerance within the airways has also been
demonstrated in animal models, in which intravenous (i.v.) adoptive transfer of Ag-specific Tregs to
OVA-sensitized mice was shown to prevent development of allergic inflammation and AHR after OVA
challenge and increase lung expression of IL-1055. This immunoregulation was essentially reversed when
an anti-IL-10R antibody was administered but not when Tregs from IL-10-/- mice were transferred,
suggesting that Tregs suppress via an IL-10-dependent mechanism but do not need to make it themselves.
Follow-up studies revealed that when delivered after disease onset, Tregs were also capable of
downregulating established inflammation and hindering airway remodeling56. Moreover, depletion of
Tregs in AHR-“resistant” C3H mice prior to the administration of HDM led to exacerbated airway
inflammation and AHR that was associated with an increase in the number of myeloid DCs, expression of
MHCII and co-stimulatory molecules on these DCs, as well as an enhanced ability of DCs to stimulate T
cell proliferation and Th2 skewing57. These data suggest that Tregs are extremely important in preventing
allergen sensitization through inhibitory effects on DC activation. Interestingly, Leech et al. showed that
naïve T cells are capable of exerting suppressive effects when transferred into Der p 1-challenged mice58,
suggesting that Tregs may not be Ag specific to suppress airway disease (though this is hotly debated).
Methods to expand Tregs, recruit them to the site of inflammation, and enhance their suppressive
potential has been the focus of many recent studies and appears to be of promising therapeutic value in
patients with asthma59,60.
Mechanisms of Treg suppression in asthma
Tregs utilize multiple suppressor functions to regulate allergic inflammation, including inhibitory
cytokine secretion, cell-contact dependent mechanisms, consumption of limiting growth factors, and
modulation of DC activity61. A few of the mechanisms will be briefly discussed in the context of asthma.
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Of inhibitory cytokines, IL-10 is among the most critical in the context of asthma. IL-10 is a
potent inhibitor of Th2 cells, APCs, and proinflammatory cytokine production62. IL-10 also increases the
ratio of IgG4 to IgE (discussed more in section IIIc). Studies in asthmatic patients have shown decreased
levels of IL-10 in the BAL when compared to healthy controls63, while children who suffer from asthma
have been shown to have decreased IL-10 mRNA levels in T cells than in healthy children64. Moreover,
IL-10 has been shown to be required for functional activation of Tregs65. TGF-β is also an important
mediator in allergic inflammation. TGF-β suppresses the activity of both Th1 and Th2 cells and
downregulates the expression of FcεRI on mast cells66. It inhibits IgE production while promoting class
switching to IgA67, which is beneficial for reducing allergic inflammation62. TGF-β also upregulates the
expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4; discussed later) on the surface of T cells.
However, the role of TGF-β in allergic inflammation is somewhat controversial, as this cytokine may also
contribute to airway remodeling62.
The question of whether IL-10 and TGF-β require cell-cell contact for Treg-mediated suppression
in the context of asthma has been explored by Joetham et al, who demonstrated that direct intratracheal
instillation of rIL-10 and rTGF-β reduced AHR in OVA-challenged mice to baseline levels, whereas
neither cytokine on its own was capable of this function65. These cytokines also exerted synergistic effects
in reducing BAL eosinophilia and Th2 inflammatory mediators, suggesting that cell-mediated contact is
not required for the anti-inflammatory actions of IL-10 and TGF-β. However, one of the major
mechanisms by which Tregs inhibit effector T cells (Teff) is through cell contact-dependent inhibition of
proliferation68. Tregs also downregulate Th2 differentiation by inhibiting transcription factors such as
Gfi-1, which otherwise help to promote Th2 expansion69. Others have shown that Tregs also have an
indirect role in regulating Th2 responses through expression of Itch, an E3 ubiquitin ligase. Itch plays a
major role in restraining Tregs from producing Th2 cytokines that, in turn, feed Th2 effector
differentiation in non-Tregs70.
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Furthermore, Tregs modulate the activity of DCs and other APCs by conditioning them to
produce immunosuppressive molecules and downregulating their capacity to activate Teff cells. Cytotoxic
T-lymphocyte antigen 4 (CTLA-4) is expressed by Tregs and other T cells upon activation and can
downregulate expression of co-stimulatory molecules (e.g. CD80 and CD86) on DCs via direct
competition with CD2849. Thus, Tregs compete with naïve T cells for access to DC co-stimulatory signals
and in turn, reduce their ability to activate Teff cells. Indeed, studies have demonstrated that the
frequency of CTLA-4+ Tregs in the sputum of asthmatic patients is significantly reduced when compared
to healthy controls71. CTLA-4-induced signaling can also promote indoleamine 2,3-dioxygenase (IDO)
activity and decreased glutathione synthesis in DCs, which leads to cell cycle arrest in T cells and further
generation of iTregs62. By binding to MHCII, expression of LAG-3 on Tregs decreases DC activation and
reduces their Ag presentation capacity. In addition, IL-10 suppresses the expression of costimulatory
molecules and proinflammatory cytokines by DCs, which also promotes additional iTreg generation.
Other suppressive actions of Tregs include inhibition of DC migration to lymph nodes in order to prevent
priming of Teff responses.
Expression of CD39 and CD73 on Tregs has been shown to generate adenosine from ATP, ADP, and
AMP. Adeosine can then engage A2A receptors on Teff cells, which downregulates NF-κB and suppresses
T cell responses72. CD39 also promotes the expression of Foxp3; decreased Foxp3 and CD39 mRNA
have both been observed in patients with moderate to severe asthma when compared to patients with mild
asthma, along with elevated levels of ROR-γt mRNA73. Thus, certain Tregs may act via CD39 to decrease
severity of asthma by stabilizing expression of Foxp3 and preventing their conversion to Th17 cells.
Other functions of Tregs include inhibitory effects on mast cells through cell-cell contact of OX40 (on
Tregs) and OX40L (on mast cells), an action which ultimately reduces calcium influx into mast cells and
prevents degranulation74.

16

e. Good cop/bad cop? Alveolar macrophages and asthma

Macrophages: a heterogeneous and plastic group of cells
In 1908, Elie Metchnikoff received the Nobel Prize for his description of phagocytosis in
macrophages. Since this critical discovery, immunologists have been obsessed with the role of
macrophages in innate immune (i.e. non-specific) host defense. However, by primarily focusing on the
microbicidal functions of macrophages, their major role in maintaining homeostasis has been largely
ignored until recently.
Perhaps the most interesting feature of macrophages is their tremendous heterogeneity and
plasticity. This allows them to effectively respond to environmental signals while preserving their role in
maintaining immune homeostasis. As of recently, a great deal of effort has focused on subtyping
macrophages into various classes that align with their primary effector functions. The concept of classic
and alternative activation, or M1 and M2, was originally adopted to mimic the Th nomenclature.
However, this classification system was soon found to be too generalized and limiting, and so the
definitions of M1 and M2 have been expanded to incorporate three major functions: host defense, wound
healing, and immunoregulation.
The term “classically activated” (M1) macrophage (CAM) was introduced in the 1960s to
describe the non-specific but Ag-dependent microbicidal activity of macrophages towards Bacillus
Calmette-Guerin and Listeria. These cells were later linked to Th1 responses; Th1 cells secrete INFγ,
which activate classically activated macrophages and stimulate their production of pro-inflammatory
cytokines (e.g. TNFα, IL-12) and free radicals75. CAMs are key mediators of the inflammatory reactions
that occur in response to both extracellular and intracellular pathogens. They have enhanced phagocytic
abilities and Ag presentation capacities76. In addition, they secrete matrix metalloproteinases, which are
important for their migration through tissue during inflammatory responses. CAMs are thought to
originate from classical CD14hi CD16lo monocytes (Ly6chi monocytes in mice)77.
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Unlike CAMs, which are critical for host defense against infectious agents, M2 macrophages are
considered to be more important for wound healing and immunoregulation. M2 macrophages are
primarily divided into two subtypes: alternatively activated macrophages (AAM) and “regulatory”
macrophages. AAMs are wound-healing macrophages that play an important role in tissue remodeling.
Like Th2 cells, they are also thought to provide protection against helminths76. IL-4 and IL-13 production
during tissue injury rapidly polarizes resident macrophages into alternatively activated cells through the
induction of STAT6, which leads to the upregulation of arginase, a pro-fibrotic marker by which these
cells are commonly identified. In addition, these cells are characterized by enhanced expression of
scavenger receptors for phagocytosis of debris (e.g. mannose receptor [CD206]) as well as chitinase-3like-protein-3 (Chi3l3; also known as YM1) and resistin-like molecule α (Relmα; also known as FIZZ1).
IL-10+ macrophages arise during late stages of the immune response in order to dampen
inflammation75. They are generated by a number of stimuli (e.g. IL-10, glucocorticoids, prostaglandins,
phagocytosis of apoptotic cells, immune complexes) that must act in concert with a TLR stimulus. As
name implies, IL-10+ macrophages produce high amounts of IL-10 and may also produce TGF-β (though
this has not been confirmed because of the significant overlap between AAM and IL-10+ macrophage
markers76).
Despite the aforementioned classification system, it is important to note that macrophages are an
extremely heterogeneous population of cells that are capable of adopting a range of phenotypes. In other
words, these cells may exhibit characteristics of more than one major macrophage subtype to form socalled hybrid populations. Thus, macrophage phenotype and function should be appropriately considered
as a spectrum rather than a strict classification system75.
Pathogenic actions of M1 and M2 macrophages in asthma

 In 2014, a panel of macrophage experts proposed that the term “regulatory” macrophage be avoided because all
macrophages are thought to have some degree of regulatory capacity233. Thus, “regulatory” macrophages will be
simply referred to as IL-10+ macrophages throughout this dissertation.

18

Although asthma is a Th2-dominant disease, both M1 and M2 macrophages have been implicated
in the pathogenesis of this disorder. Levels of INFγ, an M1-inducing cytokine, have been shown to be
elevated in asthmatic patients and correlate with severity of asthmatic inflammation78. INFγ has also been
(indirectly) implicated in the development of AHR79, as has TNFα80, a product of M1 macrophages. In
addition, TNFα has been shown to be involved in recruitment of eosinophils81 and inhibition of Foxp3+
Treg activity82. IL-6 and IL-1β, both of which are CAM products, have been shown to have direct effects
on Th2 cell cytokine production83, fibroblast activation84, and granulocyte macrophage colony stimulating
factor (GM-CSF) production85, the latter of which enhances eosinophil recruitment and survival86. High
levels of nitric oxide produced by CAMs have additionally been observed in asthmatic subjects87 and may
amplify lung injury and mucus production88.
It is no surprise that AAMs are also highly abundant in asthmatic lungs, an effect that can be
attributed to elevated levels of both IL-4 and IL-13. Indeed, it has been shown that asthmatic individuals
have a higher number of AAMs on bronchial biopsy than healthy control subjects and that this correlates
positively with declines in pulmonary function in these subjects89. Animal studies have demonstrated that
female BALB/c mice, which tend to have more severe airway disease in response to the model Ag
ovalbumin (OVA; see section IVa-IVb), have more AAMs in their lungs than their male counterparts90.
Furthermore, artificially elevating AAM numbers in male mice via intratracheal instillation of these cells
dramatically increased BAL eosinophilia, mDC migration to the lymph nodes, and Teff to Treg ratio,
suggesting a causal role for AAMs in severity of asthma (Fig 1).
Alveolar macrophages: potential suppressive actions in asthma
Of cell types that are critical for the maintenance of homeostasis in the lung, the alveolar
macrophage (AM) is among the most important. AMs are one of two major macrophage subtypes found
in the lung (the other being the interstitial macrophage; IM). They colonize the airways within the first
few days after birth (a process dependent on fetal monocytes) and proliferate in situ to maintain a resident
population of long-lived cells throughout life91. AMs are generally considered to be Siglec19

FhiF4/80+CD11c+ cells, as opposed to IMs, which are of an F4/80+Siglec-F-CD11b+CD11c- phenotype.
They can adopt both M1 and/or M2 functional markers.
As resident cells of the conducting airways and alveolar spaces, AMs are among the first cells to
encounter inhaled Ags. Because the airways are exposed to a never-ending barrage of microbial, viral,
and environmental toxins, one of the principal roles of AMs involves initiation of inflammatory responses
(via conversion to M1 cells) during times of need. However, excessive inflammation could potentially
disrupt normal gas exchange, and so AMs must also be capable of suppressing unwanted immune
responses. How these cells switch back and forth so rapidly between these two opposing functions is a
subject of great interest in the field. It has been suggested that destruction of the airway epithelium and of
regulatory ligands on this epithelium (e.g. CD200) may actually stimulate AMs to respond in a proinflammatory as opposed to regulatory manner91. In addition, pathogen-specific properties that may lead
to upregulation of specific pattern recognition receptors (PRR) on the surface of AMs and subsequent
signaling through these receptors may help to determine the overall fate of these cells in any given
situation. As the focus of this dissertation involves regulatory aspects of AMs, this function will
exclusively be considered throughout the remainder of the text. However, it is nevertheless important to
note that AMs may be pro-inflammatory and potentially pathogenic in a variety of circumstances.
Several studies have supported a tolerogenic role for M2 AMs in response to allergen challenge,
although their phenotypic classification into specific M2 subsets has not typically been reported. Careau
et al. elegantly demonstrated that depletion of AMs using liposomes instilled with clodronate (Cl2MDP)
in allergen-resistant Sprague Dawley rats promoted methacholine-induced AHR post challenge with the
model allergen OVA92. Moreover, adoptive transfer of AMs from Sprague Dawley rats into allergensusceptible Brown Norway rats prior to allergen challenge abrogated AHR responses in a dose-dependent
manner, suggesting that AMs may downregulate mast cells or other factors that promote bronchial
responsiveness. Similar findings were confirmed in mice by Bang et al93, who demonstrated a significant
reduction in OVA-induced allergic airway inflammation when unsensitized AMs were intratracheally
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transferred to AM-depleted, OVA-sensitized mice prior to allergen challenge. Depletion of AMs was also
shown to exacerbate HDM-induced allergic inflammation, as noted by elevated eosinophils, neutrophils,
Th2 cells, and Th2 cytokine and antibody responses94. Moreoever, depletion of AMs, which are critical
for phagocytosis of apoptotic cells95, also delayed resolution of the allergic response following
discontinuation of the allergen. Other studies on AM function in HDM-induced allergic models have
shown that depletion of AMs leads to enhanced recruitment of Ly6chiCD11b+ monocytes to the lungs and
exacerbation of inflammation, suggesting that while resident AMs are anti-inflammatory in the context of
asthma, monocyte-derived cells are not96. These Ly6chi monocytes may be potentially influenced towards
a pathogenic AAM phenotype following their arrival to an AM-depleted lung environment where high
levels of Th2 cytokines are present97.
One of the major mechanisms by which AMs exert their anti-inflammatory actions is through
suppression of T cell stimulation. Coleman et al. have demonstrated that while peritoneal (control)
macrophages promote 3H-thymidine incorporation by anti-CD3-stimulated naïve T cells, AMs fail to
promote this incorporation98. This effect is likely due to suppressive AM-derived soluble factors because
the same effects were noted when T cells were co-cultured with AM-derived culture media in lieu of
actual cells. One of these major factors is IL-10. As mentioned above, IL-10+ M2 macrophages exert an
immunoregulatory role in a number of diseases, and they have been shown to inversely correlate with
severity of asthma (Figure 1). Indeed, studies have demonstrated that lung macrophages produce less IL10 in steroid-naïve asthmatic subjects than in healthy subjects99 and significantly upregulate IL-10 post
treatment with traditional pharmacologic agents100, suggesting that defects in development of these cells
may predispose individuals to development of this disease. IL-10+ M2 AMs but not M1 CAMs or M2
AAMs have also been shown to be lower in the lungs of mice exposed intranasally to HDM relative to
control animals, an effect that negatively correlated with disease parameters101. IL-10-expressing M2
macrophages demonstrate enhanced indoleamine 2,3-dioxygenase (IDO) activity, which may
subsequently reduce Th2-mediated inflammation in asthma100. Additional findings suggest that IL-10+
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macrophages (IMs, in this case) may downregulate allergic inflammation and AHR by suppressing LPSstimulated DC secretion of pro-inflammatory cytokines as well as DC maturation and migration to lymph
nodes, where Ag presentation would otherwise occur102. IL-27 is another cytokine that may be important
for the regulation of inflammatory responses by AMs94.
Effects of AMs on induction of Tregs
Recent studies have suggested that one of the major mechanisms by which M2 AMs may exert antiinflammatory effects under homeostatic conditions is through the induction of Foxp3+ Treg cells, an
action that appears to be dependent on both TGF-β and retinoic acid98,103. Moreover, this conversion was
still possible even when T cells were first activated in a short-term manner by Ag-bearing lymph node
DCs103. Since AMs are not found in high frequency in the HLN, this suggests that they may act as both
secondary and tolerogenic APCs within the lung. Interestingly enough, intratracheal transfer of Ag-pulsed
AMs prior to OVA sensitization have also been shown to protect against development of allergic airway
inflammation, as is evidenced by decreased lung inflammation, Th2 cytokine production, BAL total
leukocytes, eosinophil levels, and AHR as well as increased pulmonary Tregs103. Other studies have
demonstrated that inhibiting macrophage-derived retinoic acid in vivo subsequently promotes enhanced
IgE titers when mice are first sensitized and challenged with OVA-CpG98, an effect that may also be
dependent on their induction of Foxp3+ Tregs. However, inhalation of complex allergens such as HDM
have been shown to impair AM ability to induce Foxp3+ Tregs due to stimulation of a pro-inflammatory
phenotype despite lack of effect on TGF-β or retinoic acid production103. Furthermore, production of IL10+ “regulatory” M2 AMs with prolonged exposure to a human-relevant allergen (e.g. HDM) has, to the
best of our knowledge, never before been demonstrated.
Of note, the specific role of IL-10 in induction of Foxp3+ Tregs has not been explored in great detail.
In an elegant series of experiments, Denning et al. demonstrated that lamina propria M2 macrophages are
capable of inducing Foxp3+ Tregs in an IL-10-dependent manner104. Others have shown that IL-10-
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producing macrophages are more critical for the maintenance of Foxp3 expression in the presence of
inflammation105.

III.

Why has asthma gone uncured?

“The young physician starts life with 20 drugs for each disease, and the old physician ends life with one
drug for 20 diseases.”
-

William Osler

a. Pharmacologic treatments for allergic asthma

Although science and medicine are advancing at a rapid pace, the stunning reality is that the majority
of human diseases are still lacking for cures. Asthma is among this list of diseases. Of the roughly $56
billion being spent on asthma in the United States every year, over $6 billion is being funneled towards
the costs of prescription drugs. Unfortunately, current pharmacologic agents for asthma are primarily
directed at symptom relief and have limited curative potential and poor prospects for reducing long-term
disease prevalence.
While there is no cure for asthma, it can indeed be controlled with appropriate medical care, and
routine exacerbations can be minimized by avoiding exposures to the triggering allergen. As a result,
mortality risk associated with asthma in developed countries is quite low. In the early days, asthma was
viewed as a disease of bronchoconstriction, and bronchodilators were the mainstay of treatment.
Bronchodilators are important for relief of asthma symptoms and work through their direct relaxation
effects on airway smooth muscle cells. There are three major classes of bronchodilators: β2-adrenoceptor
agonists, muscarinic receptor antagonists, and xanthines. Fast-acting agents (e.g. albuterol) have become
the primary mode of relief in emergent situations, but the major breakthrough for this class of drug was
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the advent of long-acting β2-agonists (LABA) such as salmeterol and formoterol, whose effects can last
up to 12 hours at a time106. These agents are particularly important for asthma maintenance therapy, but
are largely considered to be supplemental drugs. Overuse side effects of bronchodilators include
tachycardia, hypertension, and tolerance to β-agonists.
Inhaled corticosteroids (ICS) have revolutionized management of asthma as soon as the disease came
to be known as a chronic inflammatory disorder of the airways. The primary benefit of ICS use is that
these drugs can quickly and efficiently dampen inflammation through effects on a wide range of targets.
ICS diffuse across cell membranes, where they bind to cytoplasmic glucocorticoid receptors. This
activates the receptors, which subsequently translocate to the nucleus and modulate the transcriptional
activity of several target genes that have glucocorticoid response elements in their promoters107. ICS
work primarily by suppressing the actions of pro-inflammatory transcription factors such as nuclear
factor-κB (NF-κB) and activator protein 1 (AP1) while simultaneously enhancing the activity of antiinflammatory proteins such as inhibitor of nuclear factor-κB (IκBα), annexin-1, and IL-10108. However,
whereas ICS are very effective at broadly suppressing airway inflammation, they do not alter the specific
underlying mechanisms that contribute to asthma and thus cannot improve the natural course of disease.
In addition, their use has been linked to a range of undesirable effects including candidiasis, dysphonia,
adrenal insufficiency, bone loss, skin thinning, stunted growth, metabolic changes, and behavioral
abnormalities despite their seemingly innocent safety profile109.
Although ICS and bronchodilators have been solid agents of choice for asthma management, asthmaassociated morbidity and economic burden are nevertheless increasing as disease prevalence continues to
expand. Healthcare visits as well as the ability to purchase meds are vital to management, and cost
barriers to obtaining these services often contribute to medical emergencies. In addition, 5-10% of
asthmatics do not have well-controlled disease despite adherence to inhaled therapy (so-called “severe
asthmatics”). These patients account for a disproportionate amount of healthcare spending on asthma, as
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they are the most prone to hospitalization, high-volume medication consumption, and lost time from
work. This has increased the need to find novel and improved therapies for asthma.

b. Targeted immunologic strategies for managing asthma

Despite the fact that our current pharmacologic agents for asthma are far from perfect, our treatment
strategies for this disorder have evolved very little over the past century. A major contributor to this
problem is that despite their shortcomings, existing therapies for asthma have many desirable qualities:
they are relatively effective, safe and inexpensive. Moreover, the simple approach of pairing a LABA
with an ICS for long-term asthma management has been supported by strong scientific rationale, as these
two drugs have been shown to address complementary aspects of asthma pathophysiology110.
Nevertheless, studies in small animal models of asthma have attempted to redirect our approach to asthma
treatment, and many specific immunologic agents have been tried in humans. A handful of these
treatments will be detailed within this section.
Mast cell stabilizers (e.g. sodium cromoglicate, nedocromil sodium) were first introduced as a
treatment for asthma in 1968 and work by inhibiting chloride flux into mast cells, which increases their
threshold for activation107. Newer mast cell inhibitors have been developed since this time, many of which
inhibit mast cell chemotaxis and/or FcεRI-mediated mast cell activation. Other drugs such as montelukast
and zileuton inhibit synthesis of mast cell- and eosinophil-derived leukotrienes, which enhance
bronchoconstriction and eosinophil influx into airway tissues. However, the addition of leukotriene
inhibitors to traditional ICS regimens has been shown to be less efficacious than traditional LABA
supplementation for preventing asthma exacerbations and improving asthma symptoms, suggesting that
mast cell inhibition is not sufficient for asthma management.111
Omalizumab (anti-hIgE IgG1k) was originally designed to reduce the sensitivity of asthmatic
individuals to both inhaled and ingested allergens by binding free IgE and subsequently preventing cross-
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linking of FcεRI receptors. It received Food and Drug Administration (FDA) approval in 2003 for treating
patients with moderate to severe allergic asthma. Although omalizumab has been shown to reduce the
number of asthma exacerbations, improve lung function, and increase quality of life for many of its users,
major concerns have been raised over its high cost and long-term safety profile. In addition, omalizumab
use is contraindicated in individuals who live in areas where parasite infection is endemic.
The critical role of Th2 cytokines in development of asthma has also led to the development of
cytokine- and cytokine receptor-based immunotherapies for this disorder. This approach has required the
use of blocking monoclonal antibodies, fusion proteins, and inhibitors of Th2-associated transcription
factors such as GATA3 and STAT6107. IL-4 plays a critical role in the induction of Th2 cells and
immunoglobulin isotype switching of B cells to IgE. Many studies have demonstrated that IL-4 blockade
can attenuate allergic inflammation in animal models of AAD, however, phase 2 trials have not
demonstrated efficacy of using humanized monoclonal Abs against IL-4 to attenuate disease.112 Other
studies have assessed the effects of using humanized, IL-5-specific monoclonal Abs to reduce asthmaassociated eosinophilia. In a small, double-blind trial, these antibodies showed a dose-dependent
reduction in local and systemic eosinophils that lasted for 3 months; however, this effect did not seem to
attenuate AHR113, thereby raising doubts about the efficacy of targeting single cell types and/or molecules
for treatment of this complex disorder. The need for more effective immunologic strategies for managing
asthma is clearly substantial.

c. Allergen-specific immunotherapy as an etiologic treatment for asthma

Allergen-specific immunotherapy (ASIT) is currently the only etiologic therapy for atopic disorders
and has been in existence for over a century114. The primary difference between ASIT and other therapies
(e.g. antihistamines, antileukotrienes, bronchodilators, ICS) for asthma is that ASIT actively restores
long-term immunologic tolerance through repeated exposures to the triggering agent (i.e. is disease
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modifying), whereas the rest merely provide a temporary and non-specific suppression of inflammation
(i.e. are palliative). ASIT has been proven to be effective for treatment of allergy, allergic rhinitis, allergic
conjunctivitis, and mild to moderate asthma. Its ability to lower clinical symptom scores has been shown
to last 3 to 5 years post discontinuation of therapy115-117. In addition, administration of ASIT protects
against development of new allergies; in one study examining children aged 5-8 years with HDM-induced
asthma, half received ASIT for 3 years while the other half received symptomatic medications only118.
Three years after discontinuation of ASIT, only 25% of children who received ASIT developed new skin
test sensitivities, as compared to 67% of children in the control group. Finally, studies have indicated that
when compared to traditional pharmacologic agents, ASIT reduces medical costs by up to 80% beginning
as early as three months after initiation of therapy119, suggesting that it has enormous economic incentives
in addition to strong clinical advantages. ASIT is most commonly performed subcutaneously, but more
recently has included sublingual application.
Mechanisms of ASIT
The ultimate goal of ASIT is to induce a state of peripheral immune tolerance to the triggering
allergen. Although the specific mechanisms by which ASIT exerts its anti-inflammatory effects in
asthmatic patients are actively being investigated, as of yet, its consequences remain incompletely defined
due to the use of heterogeneous treatment protocols and treatment outcomes. Moreover, most ASIT
studies have been conducted in humans and thus have been unable to evaluate the immunologic and
physiologic changes occurring within the lungs. Nevertheless, several important patterns have emerged
from studies investigating the clinical effects of ASIT. These studies have demonstrated that ASIT
modifies the response of numerous cell types including DCs, T cells, B cells, and granulocytes. More
specifically, several papers have noted that ASIT promotes the formation of inducible Treg populations,
downregulates T effector (Teff) responses, increases the ratio of IgG4 to IgE, and decreases the activity of
basophils and mast cells. These specific mechanisms will be discussed in more detail within the following
sections:
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Tolerogenic effects on DCs and generation of Tregs: DCs in the submucosa of the airways play
an important role in the immune response against newly encountered Ags, where, as mentioned
previously, they can capture Ags and migrate to the T cell areas of the HLN. In the absence of proinflammatory signals (as does occur with ASIT), DCs maintain a partially mature phenotype120 and
display tolerogenic interactions with T cells in the lymph node121, which skews T cells towards a
regulatory (IL-10-secreting) phenotype. In addition, ASIT increases DC production of IL-10120, which
further downregulates expression of costimulatory molecules on DCs and promotes subsequent T cell
anergy.
The primary mechanism by which ASIT is thought to benefit patients with asthma and allergy is
through DC-mediated generation of iTregs. Long-term ASIT in a murine model of OVA-induced asthma
was associated with an increased frequency of Foxp3+ Tregs in the HLN that correlated with a reduction
in allergic airway inflammation and AHR122. Furthermore, depleting these Tregs during ASIT inhibits the
suppression of disease associated with this therapy123. Human studies have robustly supported the
conclusion that ASIT stimulates specific increases in Treg numbers124,125, expression of Foxp351, and
functional activity51. Other human studies have shown no differences in frequency of Foxp3+ Tregs in the
blood of asthmatic patients receiving HDM-ASIT, but have shown specific increases in levels of IL-10producing Foxp3+ T cells in the blood, a difference that became even more striking when cells were
subsequently cultured in vitro with HDM126. Furthermore, ASIT has been shown to restore the
suppressive activity of Foxp3+ Tregs51. This suppressive activity may be related to the ability of Tregs to
produce anti-inflammatory cytokines (IL-10, TGF-β) and/or expression of CTLA-4, which can curb the
responses of Teff cells and skew immunoglobulin production towards protective IgG4 (through IL-10) and
IgA (through TGF-β) subtypes67 (see below for more details). Skewing this balance between allergenspecific Treg and Teff cells appears to be critical for the correction of allergic immune responses against
innocuous substances127.
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In addition to Foxp3+ Tregs, several studies have demonstrated that ASIT increases the number of
IL-10-secreting CD4+ T cells128 and Tr1 cells122,127, both of which have been thought to play a major role
in the efficacy of ASIT. Specifically, increased local Tr1 cells have been associated with elevated IgG4
levels and blocking activity due to their enhanced production of IL-10. In a murine study of OVA-ASIT,
neutralization of IL-10 signaling abrogated the immunosuppresive effects of ASIT and led to increased
AHR, eosinophilia, IgE titers, and evidence of airway remodeling122.
Moreover, some studies have shown that ASIT also increases IL-10 production by non-dendritic
cell APCs, including monocytes and tissue macrophages129,130. These cells may, in turn, help skew T cells
towards a regulatory Tr1 phenotype.
Downregulation of T effector cells: T cells of asthmatic patients typically undergo extensive
proliferation when they come in contact with their cognate allergen. Early studies demonstrated that this
proliferative response was suppressed in patients receiving ASIT131. A series of elegant studies later
demonstrated that T cells undergo a state of peripheral anergy following ASIT in patients with bee venom
allergy, as marked by decreased production of Th2 cytokines to levels observed in nonallergic
individuals132. In most cases, the levels of Th2 cytokines produced were shown to inversely correlate with
duration of ASIT. These observations clearly indicated that ASIT accomplishes its clinical effects, in part,
through suppression of Th2 effector responses. Additionally, allergen-specific T effector (Teff) cells from
patients receiving ASIT were shown to produce increased levels of IL-10129, and neutralization of IL-10
was specifically shown to break T cell anergy and restore the ability of T cells to proliferate and produce
Th2 cytokines. Furthermore, ASIT has been associated with a shift in CD4+ T cells from a Th2 phenotype
to an INFγ-secreting Th1 phenotype133,134. This change in cytokine expression may assist in mediating the
clinical benefits of ASIT by regulating pathogenic Th2 responses. ASIT also alters responses of allergenspecific memory T- and B-cells115, thus explaining the persistence of its effects long after discontinuation
of treatment.
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Effects on immunoglobulin responses and B cells: Upon initial response to an allergen, low
affinity IgG1 antibodies are generated against the allergen. In healthy individuals that do not develop
allergy, repeated exposure to the allergen generates high affinity IgG4 antibodies against the allergen,
whereas in atopic individuals, allergen challenge results in production of IgE129. Many of the benefits of
ASIT appear to be mediated through alterations in allergen-specific immunoglobulin profiles,
specifically, decreases in allergen-specific IgE/IgG4 ratios127 through enhanced Treg activity. The
induction of IgG4 in B cells by Tregs has been shown to be dependent on GITR and IL-10 and can be
enhanced by TGF-β135 (IL-10 consequently also inhibits IL-4-mediated class switching to IgE). It is
thought that generation of Ag-specific IgG antibodies directed against the same epitopes as Ag-specific
IgE may directly compete for allergen binding and exert a “blocking” effect on IgE121. In support of this
theory, removal of IgG4 activity in the sera of patients who received ASIT resulted in a nearly complete
loss of the inhibition of allergen-IgE binding to FcεRII on B cells130. However, antibody responses that
are induced with ASIT have been shown to be functionally heterogeneous, and thus the specific
mechanisms by which IgG may benefit ASIT patients is not known (Note: Induction of IgG antibodies
specific for epitopes not bound by allergen-specific IgE would not exert a “blocking” effect and may even
amplify cross-linking of allergen-bound IgE-FcεRI complexes). A second possibility is that induction of
IgG decreases the number of B cells that undergo class switching to IgE.
In addition to IgE, studies have also shown that increased levels of allergen-specific IgA (induced
by TGF-β) have been associated with successful ASIT136. Both IgA and IgG4 represent non-inflammatory
isotypes that can counter the pro-inflammatory effects of IgE.
Suppression of mast cells/basophils: Starting from the first injection, ASIT modifies the
susceptibility of mast cells and basophils to degranulation. Studies have shown that venom
immunotherapy decreases IgE-mediated histamine and leukotriene release137. This decrease in mast cell
and basophil activity has been shown to occur much earlier than the decrease in allergen-specific IgE and
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skin test reactivity in HDM-sensitive asthmatic subjects138. Both IL-10 and INFγ release by T cells have
been implicated in this process137.
Adverse effects of ASIT
Variability in safety and efficacy profiles of ASIT regimens has limited its widespread
application within the clinic. One of the major hurdles in the popularization of subcutaneous ASIT is the
potential for side effects, which range from mild symptoms to life-threatening anaphylaxic reactions.
Given this concern, practice guidelines currently recommend that patients receive ASIT in a supervised
medical facility, where they should be monitored for thirty minutes post injection. Unfortunately, this
inconvenience has decreased the utility of ASIT for many patients that are unwilling to comply with these
procedural recommendations. Thus, alternative methods for application with improved safety profiles are
being actively investigated. Sublingual ASIT carries a reduced risk of anaphylaxis when compared to
subcutaneous ASIT and can thus be administered in the comfort of one’s home; however, the efficacy of
sublingual ASIT is lower than in subcutaneous ASIT121. Epicutaneous ASIT is also currently being
explored. Additionally, ASIT regimens that utilize recombinant T and B cell epitopes (as opposed to the
entire, intact allergen) are currently being explored for their potential to decrease severe side effects

IV.

Mouse models of asthma: what have they shown us?

a. Allergic airway disease

Animal models are valuable tools for exploring the processes that contribute to the pathogenesis of
human disease. In addition to the obvious advantages of safety and cost effectiveness relative to studying
disease in patients, animal models are far less medically complicated, making it easier to isolate the
disease process(es) of interest. Most importantly, animal models allow us to dissect (often literally) the
mechanisms that contribute to the diseases we study through use of invasive, and potentially lethal,
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procedures. It would, for example, be difficult to understand the processes that contribute to the
development of asthma if one could not isolate cells from the lung compartments. As a society, we have
invested billions of dollars into advancing the molecular tools and techniques that are currently available
to answer our most pressing scientific questions. The advent of experimental asthma models in
combination with the ability to selectively inactivate genes has allowed us to explore a variety of avenues
that may contribute to asthma pathogenesis. Although the translatability of our findings are always in
doubt whenever we utilize animal models, the benefits of this approach undoubtedly outweigh the
disadvantages: animal models stand firmly as the translational bridge between the boundaries of in vitro
work and large-scale clinical trials.
We have gained a vast array of knowledge about the mechanisms that contribute to the development
and prevention of asthma using mouse models of allergic airway disease (AAD), the murine “equivalent”
of asthma. Although mice with AAD do not manifest with all of the clinical signs and symptoms of
human asthma (e.g. wheezing, dyspnea, cough), they recapitulate many immunological and pulmonary
features associated with the disease, including eosinophilic infiltration in the lungs, activation of Th2
lymphocytes, and evidence of airway obstruction through mucus overproduction and AHR. Thus, much
can be learned about human asthma from models of AAD.
Note: The majority of murine studies that focus on AAD are conducted in either C57BL/6 or BALB/c
mice. While each strain has distinct advantages, it is important to note that the features of AAD may
manifest slightly differently depending on which strain is used, with BALB/c mice traditionally
demonstrating more significant AHR responses. The Thrall laboratory conducts its studies exclusively in
C57BL/6J mice, a model which has proven to yield high quality, reproducible results. However, all major
findings from the Thrall laboratory, including development of local inhalational tolerance (discussed in
Section IVd) have also been confirmed in BALB/c mice.
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b. Ovalbumin (OVA)-induced AAD model

The majority of experimental work on asthma has been conducted using the model Ag OVA, as it is
easy to work with and yields reproducible results. It has been so extensively studied in both acute and
chronic asthma models that it forms the basis for comparison for all future studies involving different
model Ags. Moreover, technologies to specifically track OVA-specific cells and proteins (e.g. OVA
TCR-transgenic mice, SIINFEKL [OVA dominant epitope] tetramers, anti-OVA immunoglobulins) are
abundant. Nevertheless, concerns about the OVA model have begun to arise despite the fact that it has
been so useful in elucidating the fundamental immune processes involved in the development and
resolution of asthma. Although OVA is clearly capable of eliciting AAD in mice, it is not a significant
cause of human asthma and lacks many of the complex immunological characteristics of the more
clinically relevant allergens. In addition, the route of sensitization commonly utilized with this model
(intraperitoneal [i.p.] sensitization) does not relate to the natural (inhaled) route by which humans become
sensitized. Furthermore, animals will only develop AAD if they are first immunized against OVA using
aluminum hydroxide (alum), an artificial protocol that biases the immune system towards a Th2-driven
response prior to OVA aerosol exposure139. Thus, although previous investigations in long-term models of
OVA-induced AAD have added tremendously to our knowledge of the tolerogenic mechanisms utilized
by the mucosal immune system to suppress allergic inflammation, OVA is far less structurally and
immunologically complex than the majority of human allergens140. Therefore, despite their tremendous
utility, OVA-induced models of AAD are not likely to involve the entire scope of inflammatory processes
that are involved in asthmatic responses. The need persists for more physiologically relevant models of
human asthma (see section IVd).

c. House dust mite (HDM)-induced AAD model

33

Composition of HDM
Dust mites are microscopic, non-parasitic arthropods that generate potent allergic reactions in
susceptible individuals. It has been estimated that 50-85% of all asthmatics harbor an HDM allergy141,
thus making HDM the most common allergen worldwide. Over 50,000 species of HDM have been
identified, but the two most common causes of allergy in the United States are Dermatophagoides
pteronyssinus (Der p) and Dermatophagoides farinae (Der f). Unlike OVA, HDM is an extremely
complex Ag that triggers widespread activation of both innate and adaptive immune systems. The allergic
potential of HDM rests within its body fragments as well as within its fecal pellets. These pellets are
typically 10-40 μm in diameter and can thus be inhaled and deposited within the airways with ease.
What makes HDM such a popular culprit in allergy is its ubiquitous nature; mites feed primarily
on dead human skin cells, the major component of dust. Thus, HDM can be found in any location where
dust is present. Mites typically settle on surfaces such as bedding, pillows, and upholstered furniture,
which serve as their nests. Eliminating dust, decreasing humidity, and washing clothing and sheets in hot
water are the only methods known to efficiently decrease HDM concentration.
Protease activity is a common feature of most human allergens, including fungi, pollen, pet
dander, and HDM. Mites and their fecal pellets contain over 23 different groups of proteolytic enzymes
(named by species and group number) that are vital for initiation of an allergic response. Group 1
allergens (e.g. Der f 1, Der p 1) are cysteine proteases that share sequence identity with the catalytic site
of papain, while group 3, 6, and 9 allergens are serine proteases that account for 79% of the proteolytic
activity of HDM141. These proteolytic enzymes facilitate cleavage of epithelial tight junctions in the
airway, allowing allergen delivery from the airway lumen to submucosal APCs following long-term
exposure. In addition to their effects on junctional proteins, these proteases can react with cell surface
protease activated receptors (PARs) in the airways, resulting in cytokine/chemokine production from

 Unlike most human allergens, HDM does not typically remain airborne.
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epithelial cells, enhanced degranulation of mast cells and eosinophils, bronchial smooth muscle
contraction, and maturation/proliferation of collagen-producing fibroblasts.
As mentioned in Section IIb, an important stage in asthma development is the sensitization phase,
which requires the presence of an adjuvant. LPS is a potent adjuvant that is found in abundance in HDM
extract. Thus, a major advantage of using inhaled HDM rather than aerosolized OVA to induce AAD is
that disease results after mucosal sensitization in the lungs (as is presumed to occur in humans) and does
not require peripheral sensitization with an external adjuvant. However, it is noteworthy to mention that
the role of LPS in the initiation of asthmatic responses is indeed complex, and timing and pattern may
have important effects on the development of atopy141.
In addition to its LPS activity, HDM-associated group 2 allergens (Der p 2, Der f 2) belong to the
MD-2-related lipid-recognition domain family and facilitate aggregation of TLR4. Thus, these proteins
help promote LPS-induced TLR4 activation in the absence of its co-receptor MD2. This is of tremendous
importance because bronchial epithelial cells express TLR4 but very little MD-2142, so group 2 allergens
are essential for the airway epithelia to sense endotoxin in HDM extract.
LPS induces innate immune responses through both TLR4- and TLR2-signaling activity. While
TLR2 appears to be dispensable for generating a robust allergic response to HDM, TLR4-/- mice have
been shown to demonstrate significant attenuation of eosinophilia, Th2 cytokine production, and AHR,
suggesting that HDM-associated inflammation is, in part, TLR4-dependent143. Furthermore, upregulation
of TLR4 has been shown to increase on bronchial epithelial cells following airway challenge with
HDM144, and its expression on structural cells is both necessary and sufficient for DC activation and T
cell priming in response to HDM8. Stimulation of the TLR4 pathway leads to recruitment of cytosolic
adaptor proteins (e.g. MyD88, Trif, Tram), which subsequently activate protein kinases that upregulate
production of various transcription factors involved in pro-inflammatory gene expression. These include
GM-CSF (involved in alveolar macrophage maturation) and co-stimulatory molecules on DCs and
macrophages144 in addition to TSLP, IL-25, and IL-33.
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In addition to a variety of immunogenic epitopes, HDM extract also contains a variety of
additional components, including chitins and β-glucans. The β-glucans (a component of fungal and
bacterial cell walls) bind to dectin molecules expressed on the surface of myeloid cells. This ligation has
been shown to result in the secretion of CCL20, a chemokine which stimulates recruitment of immature
DCs12. Chitin is a major component of the mite exoskeleton and serves as a multifaceted adjuvant that
stimulates accumulation of eosinophils and basophils145 as well as activation of macrophages141.
Asthmatic individuals have been shown to have elevated levels of chitinases when compared to healthy
individuals, which is important because these molecules may play a direct role in the augmentation of
Th2 responses146.
The tremendous complexity of HDM, the most globally recognized human allergen, demonstrates
why OVA is no longer the most effective tool for understanding the complex immune reactions that occur
in asthma. Studying responses to inhaled HDM (particularly long-term HDM exposure) will be much
more promising for downstream translation. However, it will certainly be valuable to compare any
findings from these HDM studies to those from long-term OVA models, as publications involving longterm HDM exposure have been quite limited. Moreover, comparing and contrasting responses to these
two different allergens, one of which is quite complex and the other of which is fairly simple, may have
tremendous power in teasing apart various mechanisms of asthma pathogenesis and disease resolution.

d. Chronic OVA exposure leads to development of local inhalational tolerance (LIT): a
summary of the Thrall laboratory findings to date

Almost 20 years ago, Dr. Roger Thrall set out on a mission to study lung remodeling in the setting of
asthma. To create a model of chronic asthma, his laboratory immunized C57BL/6 mice with three weekly
intraperitoneal injections of OVA and aluminum hydroxide, followed by up to six weeks of OVA
aerosolization. While short-term exposure (3 to 10 days) to OVA aerosol resulted in hallmarks of AAD
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(e.g. local leukocytosis, bronchoalveolar lavage (BAL) eosinophilia, peribronchiolar/perivascular lung
inflammation, and AHR), the laboratory was surprised to find that long-term (6 weeks) OVA exposure
led to resolution of AAD rather than chronic remodeling. This resolution phase was marked by drastic
decreases in BAL leukocytes, eosinophils, Th2 cytokines, perivascular/peribronchiolar lung
inflammation, and AHR147 and was presumed to represent a state of immunologic tolerance to OVA.
Follow-up studies demonstrated that this tolerance was dependent upon continuous Ag exposure148. In
addition, it was found that this tolerance was localized to the lung, as systemic responses to IgE were still
intact upon footpad challenge149. In turn, resolution of AAD with long-term, continuous OVA exposure
was termed ‘local inhalational tolerance’ (LIT).
Over the past decade, the Thrall laboratory has been actively investigating the mechanisms that
contribute to the development of LIT with long-term Ag exposure. Our group believes that understanding
these mechanisms may help to identify immunologic defects that could predispose certain individuals to
atopy and in turn, could lead to more targeted approaches for treating asthma. Previous findings from the
laboratory have demonstrated that OVA-induced LIT is associated with immunoregulatory shifts in the
leukocyte composition within the lungs; namely, a significant accumulation of Tregs within the HLN150.
Adoptive transfer of cells from the HLN of LIT mice into RAG-/- mice led to significant decreases in
eosinophil numbers and lung inflammation after OVA challenge when compared with mice that received
HLN cells from AAD mice. This suggests a causal role for HLN Tregs in the development of LIT.
Similar findings were noted when LIT HLN B cells were adoptively transferred into OVA-sensitized
mice prior to onset of aerosolization151. Follow-up studies supported this finding by demonstrating that
adoptive transfer of LIT-induced CD5+ B regulatory cells (Bregs) from the HLN led to induction of Tregs
within the lungs in conjunction with suppression of AAD152. Thus, the OVA-LIT model has effectively
shown that tolerance develops with long-term exposure to inhaled Ag and that Tregs and Bregs are
implicated in this process. However, tolerance to more complex, human-relevant Ags (e.g. HDM) has
never before been demonstrated. Thus, although it is speculated that non-asthmatic individuals can
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develop immune tolerance to HDM, this has never before been experimentally demonstrated with longterm HDM exposure (see Chapter 3 for more details).

V.

Hypothesis and project summary

Murine studies have clearly shown that long-term, continuous exposure to the model Ag OVA results
in development of immune tolerance and resolution of AAD. These studies have played a vital role in
understanding the mechanisms that contribute to the normal development of immune tolerance against
allergens, a process that is perhaps mimicked in the 90% of people who do not have symptoms of asthma.
However, as previously stated, OVA is far less complex than the majority of human allergens and is not a
clinically-relevant cause of asthma. On the other hand, HDM is a widespread trigger of human allergy and
affects anywhere from half to three quarters of all asthmatic individuals worldwide. Thus, one might
postulate that to inflict such a large proportion of the population, the immune system cannot readily
develop tolerance to HDM in the same manner that it does with OVA. Furthermore, prior studies in the
literature have not previously demonstrated resolution of AAD with long-term HDM exposure, though
this question has not been definitively addressed by any other group.
The goal of my studies was to determine whether immune tolerance can be generated following longterm exposure to HDM, the most ubiquitous and important allergen in the world. As previously stated,
this question has gone unanswered by other researchers that have conducted studies in long-term models
of HDM-induced AAD. Understanding if (and how) tolerance develops to HDM would be critically
important for 1) defining the mechanisms by which HDM results in asthma in susceptible individuals and
2) aiding in the development of enhanced or novel treatments for HDM-induced asthma and allergy.
Given the immunologic complexity of HDM and the high prevalence of HDM-induced asthma and
allergy, I hypothesized that immune tolerance (and subsequent resolution of AAD) would not be readily
mounted with long-term HDM administration as it is with OVA. Results from this dissertation project
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have demonstrated that while short-term and intermediate-term intranasal HDM exposure (2-5 weeks)
result in cardinal features of AAD, long-term HDM instillation (11 weeks) does, in fact, stimulate
immunologic tolerance to the traditional, AAD-associated Th2 response. However, unlike with OVA,
tolerance to HDM was associated with suppression of disease but not resolution of lung inflammation
(Chapter 3). Nevertheless, this state of suppression was marked by an increase in both Foxp3+ Tregs and
IL-10+ AMs at the site of inflammation, the latter of which is unique to the HDM model and has never
before been observed with long-term OVA exposure. Although these AMs were found to be nonessential
for immune tolerance against HDM (Chapter 4), in vitro studies demonstrated that AMs from tolerant
mice were indeed capable of inducing Foxp3+ Tregs and may thus have had a contributory role in
tolerance formation within the context of our continuous, long-term HDM model. Interestingly, parallel
studies in a clinically relevant, murine model of ASIT (Chapter 5) did not support a critical role for these
AMs in tolerance induction.
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Figures

Figure 1. The contributions of three major macrophage subtypes to the severity of allergic asthma in mice
and humans
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CHAPTER 2
MATERIALS AND METHODS

Animals
Female C57BL/6J (wild type; WT) and B6.129P2-Il10tm1Cgn/J (IL-10-/-) mice, 6-8 wks of age, were
purchased from Jackson Laboratory (Bar Harbor, ME) and conventionally housed in plastic cages with
corncob bedding. B6(Cg)-Il10tm1.1Karp/J (“Vert-x”; IL-10gfp) mice (originally obtained from Christopher
Karp and generously provided by Leo Lefrançois) were bred in the Center for Comparative Medicine at
the University of Connecticut Health Center, and 6-8 wk old mice of both male and female sexes were
used. Data was combined for both sexes because no differences were observed in disease phenotype
between male and female Vert-x mice.
The animal room was maintained at 22-24°C with a daily, 12 hour light/dark cycle. Chow and water were
supplied ad libitum. The protocols for animal use were approved by the Institutional Animal Care and
Use Committee at the University of Connecticut Health Center (protocol #100331-1114).

House Dust Mite Exposure Protocol
Mice were lightly anesthetized with vaporous isoflurane and intranasally (i.n.) instilled with droplets
containing 25 μg lyophilized HDM extract (equal mixture of D. pteronyssinus and D. farinae, Greer
Laboratories, Lenoir, NC) solubilized in 50 μl phosphate buffered saline (PBS). This dose has previously
been associated with peak inflammation in response to i.n. HDM and has been commonly utilized to
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induce AAD153,154. D. pteronyssinus and D. farinae were selected as model Ags based on the fact that they
comprise the two most common perennial indoor HDM species141. Total lipopolysaccharide (LPS)
content in the HDM extract was 1250 endotoxin units per mg HDM (equal to approximately 0.1 μg
LPS/mg HDM155; 0.01% contamination).
HDM was administered for five consecutive days, followed by two days of rest, for up to 11 consecutive
wks (Fig 2; henceforth referred to as “continuous” exposure model). Control groups received equal
volumes of i.n. PBS in a time-matched manner. Mice were sacrificed at after either short-term (2 wk),
intermediate-term (5 wk) or long-term (11 wk) Ag exposures. All mice were sacrificed 72 hours post
final Ag challenge.
In select experiments, two groups of animals were discontinuously exposed to HDM extract for 11 wks
(Fig 3). Group 1 mice (DiscR-) were administered HDM for 5 wks and then discontinued from HDM
exposure for the following 6 wks without any subsequent rechallenge. Group 2 mice (DiscR+) were
administered HDM for 5 wks, discontinued from HDM exposure for the following 4 wks, and then
rechallenged with 2 wks of HDM Ag.

BAL, Blood, and Tissue Analysis
At sacrifice, BAL fluid, hilar lymph node (HLN), and lung tissue from each animal were harvested and
processed for isolation and enumeration of leukocytes. For isolation of BAL leukocytes, lungs were
lavaged in situ with five, 1-ml aliquots of saline and pelleted at 600 x g for 10 min at 4⁰C. HLNs were
mechanically disrupted into single-cell suspensions and filtered through a 100 μm Nitex screen (ELKO
Filtering Co, Miami, FL). Lungs were digested with 150 U/ml collagenase (Life Technologies, Grand
Island, NY) and mechanically disrupted into single-cell suspensions, after which erythrocytes were lysed
via Tris-buffered ammonium chloride (TAC) solution (9 parts 0.83% w/v NH4Cl; 1 part 2.57% w/v Tris;
pH 7.0) at room temperature. For isolation of blood leukocytes, 100 μl of blood was drawn from the right
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ventricle and passed through heparinized capillary tubes (Fisher Scientific, Hanover Park, IL) to prevent
clotting. Red blood cells were lysed with TAC solution at 37⁰C.

For all tissue samples, total nucleated cell counts were obtained using a hemocytometer with nigrosin dye
exclusion as a measure of viability. Cytospin preparations of BAL fluid were stained with May-Grünwald
and Giemsa for differential cell analysis via light microscopy. Multinucleated macrophage frequency was
determined by manual counts after staining.

Flow Cytometry
Cells isolated from the BAL, HLN, and lung tissue were analyzed via flow cytometry using the following
monoclonal antibodies: anti-Siglec-F (E50-2440; BD Biosciences), anti-F4/80 (BM8.1; Tonbo
Bioscience), anti-CD11b (M1/70; eBioscience), anti-CD11c (N418; eBioscience), anti-MHC Class II IA/I-E (M5/114.15.2; Tonbo Bioscience), anti-CD3 (145-2C11; Tonbo Bioscience), anti-CD4 (RM4-5;
Tonbo Bioscience), anti-PD-1 (RMP1-30; Biolegend), anti-CD25 (PC61.5, Tonbo Biosciences), and anti
ST2 (RMST2-2; eBioscience). Samples were stained as previously described152. Briefly, cells were
washed in PBS containing 0.2% bovine serum albumin and 0.1% NaN3. Aliquots containing 105-106 cells
were incubated with anti-mouse CD16/CD32 (FcBlock; eBioscience) for 15 min. Cells were then stained
with 100 μl of appropriately diluted Live/Dead Fixable Blue Dead Cell Stain (Invitrogen) and surface
antibodies for 30 min at 4°C. Following staining, cells were fixed with 4% paraformaldehyde. For
identification of Tregs, cells stained with anti-CD3 and anti-CD4 were treated with Foxp3/Transcription
Factor Fixation/Permeabilization buffer (eBioscience) according to the manufacturer’s instructions and
stained with anti-Foxp3 (FJK-16s; eBioscience). Samples were run with corresponding isotype controls
on a BD LSR II (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo (Tree Star Software,
Ashland, OR).

Confocal microscopy
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Lung tissue was fixed in PLP buffer overnight at 4º C, washed with P-buffer, and placed in 30% sucrose
for 6 hours at 4º C prior to cryopreservation in OCT. 20 μm thick sections were blocked and stained in 1X
PBS supplemented with 0.05% Tween-20, 0.3% Triton-X 100, 2% FBS, 2 % goat serum, and 0.5% Fc
block. Lung sections were stained for epithelial cells, AMs, and CD4 T cells using anti-CD326 (G8.8;
eBioscience), anti-F4/80-APC (BM8; Biolegend), anti-CD11c-PE (N418; Biolegend), and anti-CD4BV421 (GK1.5; BD Biosciences). Sections were imaged on an LSM 780 microscope (Zeiss, North
Chesterfield, VA) and confocal images were analyzed using the Imaris (Bitplane AG, Zurich,
Switzerland) software program.

Histology
After sacrifice, unmanipulated lungs from animals not subjected to BAL were removed, fixed with 4%
buffered formalin, and processed in a standard manner. Tissue sections were stained with hematoxylin
and eosin (H&E) and periodic acid-Schiff (PAS) for mucus production at the University of Connecticut
Health Center Research Histology Core. Sections from all five lobes were examined via light microscopy
in their entirety and images were taken from representative regions of inflammation. Pathological scoring
for inflammation and mucus production was performed in a blinded manner by five reviewers on a
severity scale of 0 to 3 as similarly described156. For inflammation scores, a value of 0 was assigned when
no inflammation was detectable, a value of 1 for mild peribronchiolar/perivascular cuffing with
inflammatory cells, a value of 2 for significant peribronchiolar/perivascular clustering, and a value of 3
for significant clustering and airway remodeling. For mucus scores, a value of 0 was assigned when no
mucus was present, a value of 1 for occasional and punctate mucus staining in the airways, a value of 2
for presence of mucus rings in less than 10% of airways, and a value of 3 for presence of mucus rings in
greater than 10% of airways.

Determination of Immunoglobulin Levels
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At sacrifice, blood was collected from mice via cardiac (right ventricular) puncture, allowed to clot, and
serum was isolated.
For detection of HDM-specific IgE in serum, 96-well Nunc MaxiSorp flat bottom plates (Thermo
Scientific) were coated with 10 ug/ml HDM extract in sodium bicarbonate buffer (pH 9.5) for 16 hours at
4⁰C. Plates were washed with 0.05% PBS/Tween 20 and blocked for 1 hour at 37⁰C with BD OptEIA
Assay Diluent (BD Biosciences, San Diego, CA). After washing, serum samples were incubated at room
temperature for 1.5 hours and two-fold serial dilutions were performed (range: 1/20 to 1/2560). Plates
were washed eight times, whereafter samples were labeled with Biotin-SP-conjugated goat anti-mouse
IgE (Southern Biotech) followed by Streptavidin-HRP (BD Biosciences).
Detection of HDM-specific IgG1 was performed as similarly described153. Plates were coated with 2
ug/ml HDM extract in sodium bicarbonate buffer for 16 hours at 4⁰C. Plates were washed and blocked for
1 hour at room temperature with BD OptEIA Assay Diluent (BD Biosciences, San Diego, CA). After
washing, serum samples were incubated at room temperature for 1.5 hours and ten-fold serial dilutions
were performed (range: 1/20 to 1/200,000,000). Plates were washed eight times, whereafter samples were
labeled with Biotin-SP-conjugated goat anti-mouse IgG Fcγ Subclass 1 specific antibody (Jackson
ImmunoResearch, West Grove, PA) followed by Streptavidin-HRP (BD Biosciences).
Detection of total IgE was performed as similarly described157. Plates were coated with 2 μg/ml rat antimouse IgE (R 35-72) diluted in sodium bicarbonate buffer overnight at 4°C. Subsequently, coated wells
were blocked with 1X NAP-BLOCKER (G-Biosciences, St. Louis, MO) for 1 hour at room temperature.
After washing, serum samples were incubated for 1 hour at room temperature, washed, and developed
with Goat anti-mouse IgE-HRP (A1-H12) for 30 min at room temperature.
For all assays, labeling was followed by incubation with 3,3’,5,5’-Tetramethylbenzidine (TMB), and the
reaction was stopped with an equal volume of 1 M phosphoric acid. Dual absorbance at 450 nm and 570
nm was measured with a Bio-Rad (Hercules, CA) model 480 microplate reader. For total IgE, a standard
curve was created using mouse IgE kappa anti-TNP (C38-2).
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Quantification of Cytokines
Detection of cytokines was performed using a custom Milliplex MAP Mouse Cytokine Magnetic Bead
Panel (EMD Millipore, Billerica, MA). Serum samples were diluted two-fold and BAL supernatant
samples were concentrated ten-fold using Amicon Ultra Centrifugal Filter Units, 10K MWCO
(Millipore). Cells from lung tissue were processed into single cell suspension and lysed via sonication.
Cells were spun at 300xg for 5 min at 4⁰C and supernatant was concentrated ten-fold fold as described
above. Total protein levels were quantified via BCA assay; equal amounts of protein were run from each
sample. All samples were run in duplicate as recommended by the manufacturer.

Measurement of Airway Hyper-Reactivity
Airway reactivity was assessed on the basis of total respiratory system resistance (Rrs) response to
increasing doses (0-100 mg/ml) of acetyl-β-methacholine chloride (Sigma-Aldrich, St. Louis, MO). Mice
were anesthetized i.p. with 100 μg/kg nembutol sodium solution (Ovation Pharmaceuticals Inc, Deerfield,
IL). Mice underwent tracheostomies and were mechanically ventilated using the flexiVent System
(SCIREQ, Montreal, CA). To paralyze respiratory muscles prior to onset of methacholine exposure,
animals were administered 500 ng/kg i.p. pancuronium bromide (Sigma-Aldrich, St. Louis, MO). Airway
reactivity was determined by assessing forced oscillatory mechanics every 10 seconds for 4 minutes
following each methacholine challenge. EKG measurements were used to ensure viability for the duration
of methacholine challenge.

Treg induction assay
Freshly isolated CD4+CD25- Teff cells were obtained from the spleens of naïve Foxp3<tm1Kuch>
(Foxp3gfp) mice (originally obtained from Vijay Kuchroo and generously provided by Robert B. Clark)
using magnetic bead isolation (Miltenyi Biotech, Aurburn, CA) with >98% purity. These Teff cells were
cocultured with viable AMs (Siglec-F+CD11c+F4/80+) sorted from the lungs of short-term or long-term
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HDM exposed mice or long-term PBS exposed mice at a 1:1 ratio (0.15 x 106 Teffs, 0.15 x 106 AMs) in
the presence of soluble αCD3 (0.5 μg/ml; BD Biosciences) ± recombinant TGF-β (1 ng/ml; R&D
Systems, Minneapolis, MN). The cultures were performed in RPMI 1640 supplemented with 10% FCS,
200 μg/ml penicillin/streptomycin, 50 μM 2-mercaptoethanol and 4 mM L-Glutamine in 96-well roundbottom plates. After 72 hours, cells were taken out from the wells, and the intracellular expression of
Foxp3 was assessed on gated CD4+ T cells via GFP expression.
In select experiments, viable lung AMs were cocultured with naïve T cells in the presence of soluble
αCD3 and recombinant TGF-β ± anti-IL-10 neutralizing antibody (0.5 μg/ml; JES5-2A5; BD
Biosciences) and anti-IL-10R neutralizing antibody (0.5 μg/ml; 1B1.3a; BD Biosciences) as described
above. After 72 hours, cells were taken out from the wells, and the intracellular expression of Foxp3 was
assessed on gated CD4+ T cells via GFP expression.

Clodronate liposome administration
Clodronate or PBS control liposomes were purchased from FormuMax (Palo Alto, CA) and administered
i.n. once per week (7 mg/ml; 50 μl per injection) from weeks 5-9 of continuous HDM challenge to deplete
alveolar macrophages (Fig 4). Control liposomes were administered at equal volumes in a time matched
manner. Animals were sacrificed 11 weeks post initial HDM challenge.

Allergen-specific immunotherapy (ASIT) administration
Subcutaneous ASIT was administered in the nape of the neck for either short-term or long-term periods.
Short-term ASIT was performed as follows: mice were continuously administered i.n. HDM as shown in
Figure 2 for a period of 5 wks. Biweekly, subcutaneous ASIT with a standardized HDM extract (Allergy
Laboratories, Oklahoma City, OK),was initiated following development of early AAD (2 wks) and
continued for the remaining three wks (total of 6 injections) at either high (200 allergen units [AU]) or
low (20 AU) doses. Control animals received equal volumes (200 μl) of vehicle (normal saline phenol) in
a time-matched manner. Mice were sacrificed 72 hours post final HDM instillation (Fig 5A).
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Long-term ASIT was performed as follows: mice were administered i.n. HDM in a DiscR+ manner over
an 11-wk period as shown in Figure 3A. Biweekly, subcutaneous ASIT with a standardized HDM extract
(Allergy Laboratories) was initiated following development of early AAD (2 wks) and continued for the
remaining nine wks (total of 18 injections) at either high (200 AU) or low (20 AU) doses. Control animals
received equal volumes (200 μl) of vehicle (normal saline phenol) in a time-matched manner. Mice were
sacrificed 72 hours post final HDM instillation (Fig 5B).

Statistical Analysis
Statistical comparisons between groups were made via one-way analysis of variance (ANOVA) followed
by a Neuman-Keuls post hoc test. Airway hyper-reactivity and serum immunoglobulin curves were
compared via area under the curve (AUC) measurements. One-way ANOVA was then performed on
AUC data with a Neuman-Keuls post hoc test. Cytokine data and histopathology scores were compared
via Kruskal-Wallis test with Dunn’s Multiple Comparison post hoc test. For all data, values of p<0.05
were used as the significance threshold. All statistical analysis was performed using the GraphPad Prism
(La Jolla, CA) statistical software package.
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Figure 2. Continuous model of HDM-induced AAD. C57BL/6 mice were lightly anesthetized with
isoflurane and administered 25 μg lyophilized HDM extract in 50 μl PBS via intranasal (i.n.) instillation
for up to 11 wks as described in Materials and Methods. Black lines indicate days on which HDM was
administered. Mice were sacrificed (sac) after either 2 wks (short-term exposure), 5 wks (intermediateterm exposure) or 11 wks (long-term exposure). Control groups received i.n. PBS in a similar manner as
HDM.
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Figure 3. Discontinuous models of HDM-induced AAD. Animals were discontinuously (Disc)
administered i.n. HDM with (R+) or without (R-) a 2 wk HDM rechallenge. Intervals with tick marks
represent weeks when HDM was administered. Shaded intervals indicate rest periods when no HDM was
administered.

50

Figure 4. Model of alveolar macrophage depletion. Mice were continuously administered HDM for 11
weeks as shown in Figure 2. Starting at week 5, clodronate or PBS control liposomes were administered
i.n. once per week (7 mg/ml; 50 μl per injection) through week 9 to deplete alveolar macrophages (red
arrows). Control liposomes were administered at equal volumes in a time matched manner. Animals were
sacrificed (sac) post 11 weeks of Ag challenge.
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Figure 5. Model of allergen-specific immunotherapy. Animals were challenged with i.n. HDM (A)
continuously for 5 wks as shown in Figure 2 or (B) discontinuously for 11 wks with a 2 wk HDM
rechallenge (DiscR+) as shown in Figure 3. Intervals with tick marks represent weeks when HDM was
administered. Shaded intervals indicate rest periods when no HDM was administered.
Following 2 weeks of HDM administration, biweekly, subcutaneous ASIT with either low-dose (10 AU)
or high-dose (200 AU) HDM extract was administered for either (A) 3 wks; total of 6 injections or (B) 9
wks; total of 18 injections. Control animals received equal volumes of subcutaneous vehicle (normal
saline phenol). Red arrows indicate times of subcutaneous HDM-ASIT administration. All animals were
sacrificed (sac) 72 hours post final Ag challenge.
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CHAPTER 3
LONG-TERM EXPOSURE TO HOUSE DUST MITE LEADS TO SUPPRESSION OF
ALLERGIC AIRWAY DISEASE DESPITE PERSISTENT LUNG INFLAMMATION

©S. Karger AG

Introduction
Allergic asthma is a chronic and debilitating disorder of the airways that impacts nearly 300
million people worldwide. Unfortunately, current pharmacologic therapies for asthma do not specifically
alter the underlying immunopathology that contributes to disease and thus have had marginal effects on
reducing the overall rate and economic burden of asthma. It is crucial to understand the mechanisms that
contribute to the development and suppression of asthma in order to improve upon the standards of care
for this widely prevalent and costly disorder.
A vast body of literature documents that asthma results from lack of immunologic tolerance
against inhaled, environmental Ags, resulting in uncontrolled Th2 activation, pulmonary eosinophilia, and
airway hyper-reactivity (AHR)158. We147 and others156,159-161 have demonstrated that long term, continuous
exposure to an allergen can result in tolerance development and ultimate resolution of allergic airway
disease (AAD) in a variety of murine models. Although previous investigations in long-term models of
OVA-induced AAD have added tremendously to our knowledge of the tolerogenic mechanisms utilized
by the mucosal immune system to suppress allergic inflammation, OVA is far less structurally and
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immunologically complex than the majority of human allergens140. Therefore, despite their tremendous
utility, OVA-induced models of AAD are not likely to involve the entire scope of inflammatory processes
that are involved in asthmatic responses. The need persists for more physiologically relevant models of
human asthma.
HDM is the most causative human allergen worldwide. It is estimated that 50-85% of all
asthmatics harbor an allergy to HDM37,162, which suggests that the immunomodulatory mechanisms most
frequently activated in response to environmental Ags may be impaired in the presence of HDM. Current
models of HDM-induced asthma have been quite useful in understanding the multifaceted immune
response that is stimulated as a result of short-term Ag exposure153,163. Unfortunately, the clinical
relevance of these models is limited by the fact that most individuals are exposed to HDM in a long-term,
continuous manner due to the ubiquitous nature of this allergen. Furthermore, there is a shortage of
literature describing the effects of long-term HDM exposure in the lung. The few studies that have
utilized long-term models of HDM-induced AAD have focused heavily on the structural changes that
occur in the lung and have not examined the tolerogenic capacity of HDM or its long-term effects on the
immune system154,164.
Given the paucity of data on disease progression in murine models of HDM-induced AAD, the
purpose of this study was to investigate the ability of HDM to induce immunologic tolerance with longterm exposure. Our results demonstrated that short-term HDM exposure promoted development of AAD,
and long-term HDM exposure promoted suppression of disease, as was evidenced by full resolution of the
airway eosinophilia and AHR associated with acute AAD. Suppression of HDM-induced AAD was
accompanied by an increase in local Foxp3+ regulatory T cells (Treg) and a transition in alveolar
macrophages (AM) to an IL-10+ phenotype. We predict that the immunological changes revealed by this
novel, biphasic HDM model could offer tremendous insight into clinical strategies for the orchestration of
tolerance against human-relevant aeroallergens.
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Results
Short- and intermediate-term (2 and 5 wk) HDM exposure resulted in elevated eosinophil levels in the
BAL while long-term (11 wk) HDM exposure led to resolution of BAL eosinophilia
In concordance with previous studies that have examined responses to acute HDM instillation
using similar models154, we noted a dramatic (10-fold) increase in total BAL leukocytes after short-term
(2 wks) administration when compared to time-matched PBS control animals (Fig 6A). Cell counts
decreased significantly following intermediate-term (5 wks) HDM administration and remained at a
similar level following long-term (11 wks) HDM exposure. However, total BAL leukocytes remained
elevated over time-matched control animals following both intermediate- and long-term HDM exposure,
indicating persistent inflammation.
As was expected, mice exposed to PBS at all time points harbored few (<3%) eosinophils and
neutrophils in the BAL (Fig 6B). HDM-exposed mice did not show any elevation in neutrophils above
time-matched control animals. However, short- and intermediate-term exposure to HDM resulted in a
dramatic increase in eosinophil frequency when compared to time-matched control mice (p<0.001). Total
number of eosinophils was also significantly elevated after short-term HDM exposure (Fig 6C), and
although elevated after intermediate-term HDM exposure, did not reach statistical significance due to
high variation in eosinophil numbers at this time-point (35 ± 8 x 104). Despite continued elevation of
total leukocyte counts, long-term HDM exposure led to a decrease in BAL eosinophil levels that matched
frequencies found in control animals (Fig 6B). In addition, BAL eosinophil number decreased
significantly following long-term HDM exposure when compared to short-term exposure (Fig 6C). This
trend was similar to that observed for lymphocytes, which peaked in frequency (Fig 6B) and number (Fig
6C) after short-term exposure but greatly decreased following long-term HDM exposure. Together, these
findings suggest that long-term HDM exposure promotes suppression of allergic inflammation in spite of
persistent BAL total leukocyte counts.
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In PBS control mice, 95% of BAL cells were macrophages (Fig 6B). Macrophage frequency
dropped to 28±4 % in short-term HDM mice as a result of a relative increase in eosinophils and
lymphocytes (Fig 6B). Macrophage frequency rebounded to 88 ± 2% following long-term HDM
exposure, a value that did not statistically differ from levels observed in time-matched control mice.
However, absolute numbers of macrophages in long-term HDM mice increased 5-fold when compared to
time-matched control mice and 2- to 3-fold when compared to short- and intermediate-term HDM mice
(Fig 6C). Moreover, airway macrophages demonstrated dramatic alterations in their histological
appearance over the course of disease (Fig 6D). Whereas macrophages from PBS control mice appeared
small, round, and inactive (Fig 6D- upper left) at all time points, those from short-term HDM (Fig 6Dupper right) and intermediate-term (Fig 6D- lower left) HDM-exposed mice were more elongated,
vacuolated, and began to show evidence of multinucleation, Fig 6D,E). Macrophages from long-term
HDM mice increased dramatically in size compared to control, short-term HDM, and intermediate-term
HDM-exposed macrophages (Fig 6D- lower right). In addition, there was a substantial increase in the
frequency (Fig 6E) and number (Fig 6F) of multinucleated macrophages at this time point when
compared to those found in control, short-term HDM, and intermediate-term HDM exposed animals, thus
indicating that macrophage phenotype was altered over the course of disease.

Serum IgE titers and associated Th2 cytokines were elevated following HDM exposure
Serum levels of HDM-specific IgE were at the lower limit of detection in PBS control animals
and appeared to increase steadily over the course of HDM exposure (Fig 7A). However, as compared to
time-matched PBS controls, significant elevations in HDM-specific IgE were observed only in long-term
HDM-exposed mice, which was most likely due to the high variability observed in the more concentrated
serum samples. Serum levels of HDM-specific IgE in long-term HDM mice were also significantly
elevated over short-term and intermediate-term HDM mice, suggesting ongoing systemic allergic
inflammation. HDM-specific IgG1 levels followed a similar trend as HDM-specific IgE, increasing
steadily over the course of HDM exposure and peaking following long-term instillation (Fig 7B).
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Further evaluation of allergic status was determined via levels of Th2-associated cytokines in
HDM-exposed mice. Levels of IL-4 in BAL fluid and lung tissue of short-term HDM-exposed mice were
significantly increased over time-matched PBS control animals but decreased following long-term HDM
exposure (Fig 8). IL-5, which did not appear to be greatly elevated in the BAL fluid of HDM-exposed
mice, was, however, significantly increased in the lung tissue with short-term HDM exposure and
decreased with long-term HDM exposure. These trends were reversed in the serum; IL-4 and IL-5
appeared to steadily rise over the course of disease, demonstrating additional evidence of ongoing,
systemic inflammation. In addition, the pro-regulatory cytokine IL-10 appeared to increase in the serum
over time, although no significant differences in IL-10 levels were noted between groups. IL-10 was not
detectable in the BAL fluid and detectable only at very low levels in the lung tissue.
Th1 cytokines such as INFγ have been shown to inhibit Th2 cytokine functions and allergic
eosinophilia when acting on the airway epithelium165. Local (BAL and lung tissue) INFγ levels
approximated or fell below the limit of detection in HDM-exposed mice at all time points (Fig 8).
Intriguingly, INFγ levels appeared to be elevated in the serum of select mice exposed to HDM for either
an intermediate- or long-term period. However, these levels were not statistically increased above PBS
control mice or short-term HDM mice at either time point due to extremely high variation within groups.

Perivascular and peribronchiolar inflammation was elevated in the lungs of long-term HDM mice
despite attenuation of mucus production
As anticipated, PBS control animals demonstrated little to no histological evidence of lung
inflammation (Fig 9A,I). Early histological alterations were observed after short-term (2 wks) HDM
exposure in the form of small, inflammatory pockets (Fig 9B; short arrow) and increased following
intermediate-term (5 wks) HDM exposure in the form of large perivascular and peribronchiolar
inflammatory clusters (Fig 9C; short arrow). These clusters were diffuse throughout the majority of the
lung lobes and qualitatively consisted of lymphocytes, macrophages, and eosinophils. In addition, the
appearance of smooth muscle hypertrophy around the airways was qualitatively evident at this time point
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(Fig 9D; long arrow). Although BAL eosinophilia was attenuated in long-term HDM mice (Fig 6B,C),
diffuse peribronchiolar and perivascular inflammation in the lung tissue peaked at this time point (Fig
9D; short arrow). Semi-quantitative analysis supported an increase in inflammation above time-matched
PBS controls (Fig 9I). The composition of this inflammation, however, changed relative to short- and
intermediate-term HDM mice such that it was predominantly comprised of macrophages and lymphocytes
with few eosinophils present. No further increase in smooth muscle hypertrophy was noted in long-term
HDM mice (Fig 9D; long arrow). In addition, Mallory’s trichrome-stained lung sections did not reveal
gross increases in perivascular or peribronchiolar collagen deposition in long-term HDM mice when
compared to other stages of the model (data not shown).
In PBS control animals, there was no evidence of increased mucus production in smaller airways
(Fig 9E). Animals exposed to HDM for short-term and intermediate-term periods demonstrated increased
mucus production relative to time-matched PBS control mice via positive PAS staining of goblet cells in
smaller airways (Fig 9F,G; arrows), a conclusion which was supported by blinded scoring results (Fig
9J). Despite the presence of large inflammatory aggregates surrounding many airways, mucus production
appeared to be attenuated in airways of long-term HDM mice when tissue samples were blindly scored
(Fig 9H; arrows and Fig 9J). Although resolution of airway eosinophilia, decreased Th2 cytokines in the
lung compartments, and attenuated airway mucus production suggested that long-term exposure to HDM
led to suppression of allergic inflammation, elevated BAL leukocyte counts and
peribronchiolar/perivascular inflammation nevertheless persisted at this stage of the model.

Lung resistance was elevated by intermediate-term HDM exposure and was ameliorated by long-term
HDM exposure
In order to determine whether resolution of BAL eosinophilia and attenuation of mucus
production with long-term (11 wk) HDM exposure correlated with improved airway dynamics, AHR was
assessed in response to methacholine challenge in both PBS control and HDM-exposed mice. Baseline
respiratory system resistance (Rrs) measurements in PBS mice at the 2 wk, 5 wk, and 11 wk time points
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were virtually identical and were thus pooled to obtain a single curve representing all PBS-exposed
animals. As expected, Rrs measurements in PBS-exposed mice and all groups of HDM-exposed mice
were similar prior to methacholine administration (Fig 10). Administration of methacholine led to a dosedependent increase in Rrs measurements over a range of 1.25 to 100 mg/ml. Compared to PBS mice,
short-term (2 wk) HDM mice demonstrated increased resistance in response to intermediate doses of
methacholine, although the overall AUC of Rrs did not statistically differ from that of the PBS control
cohort. However, intermediate-term (5 wk) HDM mice demonstrated a significant elevation in Rrs when
compared to PBS subjects. Rrs for intermediate-term HDM mice was also significantly elevated over
short-term HDM mice, suggesting that intermediate-term HDM exposure led to peak airway dysfunction.
The increase in AHR at 5 wks was completely diminished with long-term HDM administration, such that
Rrs curves in PBS mice and long-term HDM mice did not statistically differ from one another. The
correlation between resolution of airway eosinophilia (Fig 6B,C) and AHR provided additional evidence
that long-term exposure to HDM promoted suppression of AAD despite persistent
perivascular/peribronchiolar lung inflammation.

Suppression of AAD with chronic HDM administration was dependent on continuous Ag exposure
Previous studies from our laboratory have demonstrated that resolution of disease following
chronic exposure to OVA is dependent on continuous Ag administration148. In order to determine whether
suppression of AAD occurs in the absence of continuous exposure to HDM, select groups of mice were
discontinuously administered HDM for 11 wks as described in Chapter 2, Fig 3. Mice that did not receive
an HDM rechallenge (DiscR-) following initial discontinuation of HDM showed similar numbers of total
BAL leukocytes (Fig 11A) and frequency of airway eosinophils (Fig 11B) as mice that received
continuous HDM for 11 wks. This finding suggested that AAD resolved spontaneously with time in the
absence of continued HDM exposure. Of interest, however, the total number of macrophages remained
elevated in the DiscR– mice as in the continuous animals, at a level approximately 9 times higher than that
seen in naïve mice.
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On the other hand, mice that received a 2 wk HDM rechallenge (DiscR+) following
discontinuation of Ag demonstrated a significant increase in total BAL leukocyte counts (Fig 11A) when
compared to both 11 wk continuous and DiscR- mice. Macrophage frequency decreased significantly
when compared to continuously exposed mice (Fig 11B). Additionally, DiscR+ mice demonstrated a
significant increase in eosinophil frequency when compared to 11 wk continuous mice (Fig 11B). Despite
the fact that eosinophil frequency increased significantly in DiscR+ mice when compared to 11 wk
continuous mice, levels reached only 21 ± 4% following 2 wk HDM rechallenge, half of that observed in
naïve mice subjected to short-term (2 wks) HDM exposure (Fig 6B). Together, these data suggested that
although continuous Ag exposure was required to actively suppress BAL eosinophilia, prior Ag exposure
may attenuate severity of allergic inflammation during re-exposure to the triggering allergen.
Attenuated disease in DiscR+ mice when compared to short-term HDM mice suggests that T cells
may become exhausted with prolonged courses of HDM exposure. To determine whether the tolerant
phenotype observed with long-term HDM exposure could be attributed to exhaustion, expression of
programmed death 1 (PD-1), whose high expression on T cells is associated with exhaustion, was
examined on CD4+ T cells in naïve, short-term HDM, and long-term HDM mice. When compared to
naïve mice, frequency of PD-1hi CD4+ T cells in short-term mice were significantly increased in all three
lung compartments (Fig 12). However, this frequency was not increased in long-term HDM mice when
compared to short-term HDM mice, suggesting that T cells were not further exhausted with prolonged
HDM exposure.

Suppression of AAD with long-term HDM instillation correlated with an increase in regulatory
leukocytes at the site of inflammation
Previous data from our laboratory have shown that key interactions facilitating tolerance to
inhaled Ags occur at the site of inflammation150,152. As a result, we examined percentages and total
numbers of Foxp3+ Tregs in the lung compartments (BAL, HLN, and lung tissue) over an 11-wk course
of HDM exposure. When compared with time-matched PBS control mice, short-term (2 wk) HDM60

exposed mice demonstrated a significant increase in the frequency of Foxp3+ T cells relative to total CD4+
T cells in the BAL and lung tissue, while intermediate-term HDM-exposed mice showed an increased
Foxp3+ Treg frequency solely in the latter compartment (Fig 13A,B). Foxp3+ Treg frequency in the BAL
and lung tissue was not further elevated in long-term (11 wk) HDM-exposed mice when compared to
short- or intermediate-term HDM-exposed animals. Total numbers of Foxp3+ Tregs in the BAL and lung
tissue were significantly increased over PBS control mice at each time point due to general increases in
total leukocyte counts with HDM exposure (Fig 6A) but were not increased in long-term HDM mice
relative to short-term or intermediate-term HDM mice (Fig 13C).
Foxp3+ Treg frequency among total CD4+ T cells in the HLN was approximately 14 ± 2% in PBS
control groups and was not significantly elevated with short-term or intermediate-term HDM exposure
(Fig 13A,B). However, long-term HDM-exposed mice demonstrated significant increases in HLN Foxp3+
Treg frequency (20 ± 2%) when compared to time-matched PBS control, short-term HDM and
intermediate-term HDM animals. In contrast, total numbers of Foxp3+ Tregs in the HLN demonstrated
steady expansion over the course of HDM exposure, with significant elevations in intermediate-term
HDM animals over short-term HDM mice and in long-term HDM mice over both short-term and
intermediate-term animals (Fig 13B). Most intriguingly, these kinetics correlated with resolution of
eosinophilia in the airways (Fig 6B,C). Of note, no major differences were observed in the frequency of
total CD4+ T cells in the HLN across the various stages of the model (Fig 14). These findings suggest that
selective expansion of Tregs in the HLN may play a critical role in suppression of AAD following longterm Ag exposure.
In addition to T regulatory cells, there is growing evidence that M2 macrophages can exert
regulatory effects in the context of asthma. Because alveolar macrophages (AMs) are the predominant
cell population within the naïve airway and because they increased in frequency and number in long-term
HDM mice (Fig 6B,C), we examined changes in M2 alveolar macrophage status (F4/80+CD11c+ cells;
Fig 15A) throughout the course of the model. Production of IL-10 (a hallmark regulatory cytokine
produced by M2 macrophages75) was examined by administering HDM or time-matched PBS control to
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IL-10-GFP reporter (Vert-x) mice both short-term (2 wks) and long-term (11 wks) as described in Fig 2.
While neither PBS nor short-term HDM administration increased IL-10 production by AMs in the BAL
or lung tissue when compared to negative control animals, AMs from long-term HDM mice demonstrated
a rightward shift in GFP expression indicative of elevated IL-10 production (Fig 15B). This shift
represented a significant increase in mean fluorescence intensity (MFI) of IL-10-GFP in long-term HDM
mice relative to time-matched PBS animals and short-term HDM animals in both BAL and lung tissue
(Fig 15C). Frequency of IL-10+ AMs in short-term HDM exposed to HDM was not increased over levels
observed in time-matched PBS animals in the BAL and lung tissue (Fig 15D). However, frequency of IL10+ AMs was significantly increased over time-matched PBS animals and short-term HDM animals in
long-term HDM mice. Of note, no differences in frequency of IL-10+ macrophages were observed
between PBS animals at either time point, demonstrating that induction of IL-10+ macrophages was
specific to HDM administration. Quite interestingly, induction of IL-10+ macrophages with long-term
HDM administration was observed only in F4/80+CD11c+ AMs and not in F4/80+CD11c- interstitial lung
macrophages (IMs; Fig 15E). Forward and side scatter analysis of IL-10+ AMs demonstrated that these
cells were large in size and highly granular (data not shown), thus correlating with the appearance of big,
densely staining macrophages in the BAL after 11 wks HDM administration (Fig 6D).
Because disease severity was less pronounced in DiscR+ mice when compared to acute (2 wk)
HDM mice, we examined whether AMs adopted an IL-10+ M2 phenotype in mice that were
discontinuously administered HDM. AMs in DiscR+ mice produced similar levels of IL-10 in the BAL as
AMs from mice administered HDM continuously for 11 wks (Fig 16). Furthermore, both 11 wk
continuous and DiscR+ AMs in the BAL produced significantly more IL-10 than AMs in DiscR- mice
(p<0.001). However, neither DiscR- or DiscR+ AMs in the lung produced much IL-10 when compared to
11 wk continuous AMs.
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Discussion
The allergic response to inhaled HDM has been extensively characterized in its acute stages;
however, few studies have examined the effects of long-term, inhaled HDM exposure on the
inflammatory response. The present findings demonstrate that inhaled HDM exposure stimulated a
biphasic response, in which short-term (2 wk) and intermediate-term (5 wk) intranasal exposure incited
hallmarks of AAD (elevated BAL eosinophilia, mucus production, and AHR upon methacholine
challenge) and long-term (11 wk) exposure promoted suppression of allergic inflammation (decreased
BAL eosinophilia and mucus production with lack of AHR). Interestingly, long-term HDM mice
maintained persistent perivascular/peribronchiolar, mononuclear cell inflammation within the lungs.
Our laboratory has previously demonstrated that continuous aerosol administration of the model
Ag OVA leads to a biphasic response in which short-term exposure promotes development of AAD that
resolves following long-term exposure147. Long-term HDM administration showed a similar pattern to
the long-term OVA model: suppression of AAD with decreased BAL eosinophilia, decreased mucus
production, and resolution of AHR upon methacholine challenge. In support of our findings, others have
also observed attenuation of BAL eosinophilia during long-term HDM exposure; however, this
observation has previously been noted in conjunction with increased airway neutrophilia and significant
vascular remodeling164,166,167, indicators of progressive AAD rather than attenuated AAD. The reason for
this discrepancy between models is not entirely known, but one might speculate that this could be a
consequence of strain differences, as the previously referenced studies were all performed in BALB/c
rather than C57BL/6 mice. It has, in fact, been shown that BALB/c mice exposed intratracheally to the
fungal allergen Aspergillus fumigatus demonstrate a neutrophil predominance when compared with
C57BL/6 mice due to augmented TNFα production by dendritic cells and macrophages168. Moreover,
TNFα has been shown to influence vascular and lymphatic remodeling in mice with sustained airway
inflammation169. In addition to strain, dose and timing of HDM exposure are likely to affect the
phenotype observed in this model. While it is well-established that tolerance development generally
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requires long-term allergen challenge, the dose of HDM required for tolerance generation is a trickier
matter, as tolerance to long-term HDM exposure has not previously been demonstrated. While others
have shown limited dependency of allergen dose on pathology, cytokine responses, and AHR in shortterm, HDM-exposed mice170, dose effects on long-term HDM exposure have not been well characterized
and require appropriate follow-up studies.
Although the effects of long-term OVA exposure on suppression of methacholine-induced AHR
are well established, this study is the first to relate resolution of eosinophilia with concurrent suppression
of AHR in an HDM model. The reason for suppression of AHR with long-term HDM challenge is not
definitively known, and it is not guaranteed that the reduction in eosinophils had a causal role in this
response171. Although one group has shown that long-term (20 weeks) HDM exposure does not result in
resolution of AHR166, in their study, HDM was administered only three times per week as opposed to
five. Thus, continuous Ag instillation (a hallmark of both our OVA and HDM protocols) may be required
for tolerance induction and subsequent suppression of AAD. In addition, a causative role between mucus
overproduction and development of AHR has been described172. Relative to short-term and intermediateterm HDM-exposed animals, long-term HDM mice demonstrated a noticeable reduction in mucus within
the airways. This reduction in mucus may have directly contributed to the resolution of AHR observed
with long-term HDM exposure.
Despite the relative reduction in local inflammatory responses observed in long-term HDM mice
when compared to short-term HDM mice, the former group demonstrated higher HDM-specific IgE
levels and Th2 cytokines systemically. Persistent (or even increased) systemic IgE responses with longterm, inhalational Ag exposure has been previously demonstrated by our laboratory148 as well as by
others156. Moreover, our previous findings indicate that mice that develop tolerance with long-term OVA
exposure demonstrate greater subcutaneous late phase responses after OVA footpad injection than shortterm OVA-exposed mice149. Thus, it appears that development of tolerance to inhaled allergens with longterm exposure is a localized response that is not dependent upon suppression of systemic inflammation.
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Nevertheless, trending increases in IL-4 and IL-5 in the serum of long-term HDM mice was matched by
increased IL-10 levels, suggesting some degree of systemic immunoregulation as well. Additionally,
systemic HDM-specific IgG1 responses were also increased over the course of Ag exposure and were
significantly elevated in long-term HDM mice relative to short- and intermediate-term HDM mice.
Successful courses of allergen-specific immunotherapy (the only etiological therapy for treatment of
asthma and allergy) is commonly associated with increases in IgG1 (murine equivalent of IgG4 in
humans) in both mice122 and humans173. Murine IgG1/human IgG4 have been thought to act as blocking
antibodies that can compete with IgE for allergen binding. Thus, systemic increases in IgG1 with longterm HDM exposure may serve as an additional indication of tolerance development within this model.
Successful courses of allergen-specific immunotherapy have also been associated with immunodeviation,
during which T helper cells shift from a predominantly Th2 to Th1 phenotype174. Although Th2 cytokines
appeared to decrease locally following long-term HDM exposure, we did not observe any evidence that
such a shift occurs within our model. INFγ levels remained at or below the limit of detection in local
(BAL and lung tissue) compartments. Although INFγ levels appeared to be elevated in the serum with
intermediate-term and long-term HDM exposure, they were associated with extremely large variations
within groups. Thus, this data suggests that a switch from Th2 to a Th1 phenotype is not likely to explain
suppression of AAD with long-term HDM exposure.
Most intriguingly, the inflammatory pattern associated with long-term HDM instillation
demonstrated some key differences from that associated with long-term OVA administration. The time
course of AAD induction and resolution differed, with peak AAD occurring after 7-10 days of airway
exposure to OVA and resolution developing after 6 wks of exposure147. A longer time course was needed
for HDM, with peak AAD seen after 5 wks of exposure and resolution of the AAD responses requiring 11
wks. Moreover, long-term OVA administration is marked by full resolution of perivascular and
peribronchiolar inflammation in the lung tissue, a decrease in total BAL leukocyte counts to baseline
levels, and little evidence of airway remodeling147,175. In contrast, mice exposed to long-term HDM (11
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wks) had persistent inflammation in their BAL and lung tissue with some evidence of airway remodeling
(in the form of smooth muscle hypertrophy). While smooth muscle hypertrophy was qualitatively
increased in long-term HDM mice relative to short-term HDM mice, little difference was noted when
compared to airway smooth muscle in intermediate-term HDM mice. These findings are supported by
previous work, which demonstrates that airway smooth muscle mass increases with 5 wks of HDM
exposure but does not further enlarge with 10 wks of HDM exposure176. However, in our model, the
inflammatory composition in long-term HDM mice changed from eosinophilic (2 and 5 wks) to
mononuclear (11 wks) in nature. Persistent mononuclear inflammation in spite of attenuated mucus
production and AHR may be attributed to the complexity of HDM, which is comprised of numerous
immunogenic compounds with various biological properties, including LPS, β-glucans, chitin, and
enzymatically-active proteases141,177.
The role of LPS in the pathogenesis and regulation of allergic responses has long been of interest
to the scientific community. TLR4 signaling from contaminating LPS in HDM extract has been clearly
confirmed to contribute to the development of HDM allergy, particularly with regards to mucosal
sensitization and initiation of Th2 polarization8. Yet despite the fact that mice are continuously exposed to
LPS within this model, neutrophils (a key responder in LPS-mediated inflammation) are not significantly
elevated at any observed time point following HDM exposure. As has been previously demonstrated, it is
likely that neutrophils were only transiently elevated within the BAL for hours following initial allergen
challenge, after which time they were replaced by eosinophils178. Thus, LPS is not likely to have had a
critical role in the phenotypes observed within later stages of this model. Moreover, we have previously
demonstrated that chronic inhalation of LPS in an aerosol solution is not required for development of
immune tolerance to long-term OVA exposure, which is especially noteworthy because our OVA and
HDM extracts have similar LPS contents179. Nevertheless, OVA is a simpler Ag than HDM in all other
regards. The numerous compounds in HDM may induce innate immune responses by binding proteaseactivation receptors (PARs), Toll-like receptors (TLRs), or C-type lectin receptors (CTRs) in innate
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immune cells such as macrophages and mast cells180 and in airway epithelial cells181. It is possible that
continued activation of these innate pathways resulted in persistent inflammation and smooth muscle
hypertrophy in the long-term HDM model despite apparent development of airway tolerance to HDM.
Persistence of inflammation with long-term HDM exposure could represent ongoing, non-eosinophilic
asthma, analogous to the paucigranulocytic asthma seen in a third of adults with asthma, including
subjects with HDM sensitivity182. However, paucigranulocytic asthmatics demonstrate
hyperresponsiveness to methacholine182 – unlike the resolution of AHR seen in our long-term HDM
animals. Thus, long-term HDM-exposed mice appeared to have regained respiratory tolerance to HDM,
perhaps analogous to the 60-70% of childhood asthmatics in whom asthma remits by puberty183-185. In this
regard, it is intriguing to speculate that potential subclinical lung inflammation (in the absence of airway
eosinophilia, methacholine AHR, or asthma symptoms) could play a role in the relapse of asthma in 4050% of remitted individuals in later adulthood183-185.
Respiratory tolerance to common aeroallergens has been shown to involve a variety of leukocyte
populations, the most established of which is the Foxp3+ Treg. Studies have shown that patients with
asthma have a deficiency in Foxp3+ Treg levels49,50 and that induction of Tregs (e.g. through
corticosteroid use and immunotherapy) can play a crucial role in altering the progression of allergy and
asthma186,187. Foxp3+ Treg frequency was elevated in the HLN specifically with long-term but not shortterm or intermediate-term exposure, a finding that has not been reported in previous studies that have
administered HDM for long-term periods. Intriguingly, absolute numbers of Foxp3+ Tregs in the HLN
(but not in the BAL or lung tissue) demonstrated steady expansion over the course of HDM exposure.
Moreover, the kinetics of Treg proliferation occurred prior to suppression of disease, suggesting a causal
role for HLN Tregs in tolerance development. Previous findings from our OVA model demonstrate that
Treg accumulation in the HLN correlates with development of immune tolerance150 and that this
induction occurs specifically through interactions with B regulatory cells152. Thus, increases in HLN
Tregs with long-term HDM exposure may have played an important role in the suppression of AAD. Of
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note, T cell exhaustion is not likely to have contributed to the phenotype observed with long-term HDM
exposure since the frequency of PD-1hi CD4+ T cells in all three lung compartments was not increased at
this time point when compared to short-term HDM mice; however, this possibility should be more
definitely ruled out via lymphoproliferative assays and examination of other exhaustion markers in
combination with PD-1 (e.g. LAG-3).
In addition to increased Tregs, long-term HDM-exposed BAL and lungs showed elevations in
macrophage numbers. These macrophages were morphologically distinct from those observed at other
stages of the model in that they were larger in size and often multinucleated, suggesting that they may
exhibit different functional characteristics. Other studies have also demonstrated that long-term dosing
regimens with HDM extract leads to the formation of large, activated, multinucleated macrophages in the
lungs, although these macrophages have not previously been further characterized188. Macrophages that
undergo fusion with other macrophages to form multinucleated cells are a prominent feature of some
chronic inflammatory states in the lung, including sarcoidosis and hypersensitivity pneumonitis. On the
other hand, multinucleated giant cells have also been implicated in the clearance of lung eosinophils
through phagocytosis189, which may explain the disappearance of eosinophils in chronic HDM mice.
Macrophage fusion is enhanced by factors that contribute to the generation of an M2 phenotype, including
IL-4 and IL-13190,191. Additionally, GM-CSF has been shown to promote AM differentiation into
multinucleated macrophages192, and HDM-induced AAD has been shown to be dependent on endogenous
GM-CSF production153. Further studies in IL-10-GFP reporter mice demonstrated that AMs in BAL and
lung tissue of long-term HDM mice exhibited an enhanced ability to produce the anti-inflammatory
cytokine IL-10 relative to AMs in both short-term HDM-exposed mice and time-matched PBS control
animals. It is currently undetermined as to why long-term exposure to HDM would induce this
phenotypic switch in macrophages, although it has been postulated that chronic TLR4 signaling through
LPS exposure may stimulate this response as a feedback mechanism for curtailing inflammation193.
However, we have not observed multinucleated giant AMs in our long-term OVA model, suggesting that
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LPS alone is not responsible for this phenotypic switch. Interestingly, enhanced production of IL-10 with
long-term HDM exposure was found exclusively in AMs and not IMs. This observation directly contrasts
with previous evidence that suggests IMs, and not AMs, assume an IL-10+ phenotype upon exposure to an
allergen in the presence of LPS102. Intriguingly, studies have demonstrated that IL-10+ macrophages are
critical for the maintenance of Foxp3 expression in mucosal Tregs105. Thus, it is possible that IL-10+ AMs
from long-term HDM mice may have exerted indirect suppressive effects on AAD through their Tregenhancing activity. IL-10 has been shown to play an important role in regulating the severity of
AAD194,195 and is often decreased in the BAL of asthmatic patients relative to healthy controls63.
Moreover, it has been shown that in the setting of asthma, AMs have a reduced capacity to produce IL-10,
and that inhaled steroids used for asthma treatment can increase AM capacity to express IL-10196.
However, it remains to be known whether the IL-10+ AMs induced by chronic HDM exposure are indeed
active contributors to disease suppression or simply markers of a tolerogenic lung environment. This
question will be further explored in Chapter 4.
As we have observed in the OVA model, disease suppression in this HDM-induced model of
AAD was dependent upon continuous administration of Ag148. Thus, when DiscR+ mice were
subsequently rechallenged with HDM, BAL eosinophilia was elevated when compared to levels in
continuous and DiscR- mice. However, the fact that frequency of eosinophils in the BAL of DiscR+ mice
was only half of that observed after 2 wk HDM challenge in naïve mice suggested that prior exposure to
HDM attenuated disease severity upon restimulation. These findings may be pertinent to the concept of
allergen-specific immunotherapy (ASIT), an etiological therapy for asthma in which repeated
administration of the triggering allergen decreases the threshold of reactivity to this causative substance.
Multiple studies have demonstrated that ASIT confirms many of its immunological benefits for years
even after discontinuation of therapy115,116, although the exact reasons for this are still unknown. Based on
this observation, it would seem likely that DiscR+ mice exposed to a 2 wk HDM rechallenge may have
had more opportunity for tolerance development during the initial 5 wk HDM exposure period than naïve

69

mice exposed to 2 wks of HDM, and in turn the former population may have been less prone to
developing BAL eosinophilia than the latter. This speculation was supported by the finding that AMs in
the BAL of DiscR+ mice produced similar levels of IL-10 as AMs in 11 wk continuous mice, whereas
AMs from 2 wk HDM mice did not. Interestingly, ASIT has been shown to enhance IL-10 production in
tissue-resident macrophages130.
In summary, the aforementioned data provides the first evidence that continuous, long-term HDM
exposure leads to suppression of AAD associated with short- and intermediate-term HDM exposure,
including resolution of eosinophilia and AHR. Furthermore, suppression of AAD coincides with increases
in Foxp3+ Tregs in the HLN, a finding previously observed with long-term OVA exposure but never
before reported for HDM. However, fundamental differences from the OVA model were noted with longterm HDM instillation, including persistent mononuclear inflammation in the peribronchiolar/perivascular
regions of the lung despite abrogation of AHR as well as the formation of IL-10+ AMs. We believe that
results from this long-term HDM model are more clinically representative of the processes involved with
tolerance development in human subjects. Thus, this model has tremendous utility for exploring the
mechanisms governing immune regulation against complex aeroallergens. Furthermore, continued
investigation into this clinically-relevant, biphasic mouse model of AAD may subsequently lead to more
successful approaches for tolerance induction in individuals with asthma.
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Figures

Figure 6. BAL eosinophilia peaks with short-term HDM exposure and resolves with long-term HDM
exposure. Female C57BL/6 mice were exposed i.n. to PBS or HDM extract for up to 11 wks as described
in Chapter 2, Fig 2. (A) At sacrifice, total BAL leukocytes were harvested and manually counted on a
hemocytometer. (B-D) Cytocentrifuged preparations were stained with May-Grünwald Giemsa and
differential analysis was manually performed. For (D), the four panels represent: short-term PBS control
(upper left); short-term HDM (upper right); intermediate-term HDM (lower left); long-term HDM (lower
right). X60, scale bar = 20 μm. (E-F) Further analysis was performed on macrophage populations from
(D) and percentage (E) and number (F) of multinucleated versus mononucleated macrophages were
manually determined. Values for (E) are shown as a percentage of multinucleated macrophages out of
total macrophages. Data represent mean ± SEM values; n = 8-13 per group (PBS; values pooled from 2-3
independent experiments), 16-21 per group (HDM; values pooled from 3-5 independent experiments). (A,
E-F) **p<0.01, ***p<0.001 vs time-matched PBS control; †p < 0.05, ††p<0.01, †††p<0.001 vs. short-
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term HDM; ‡‡‡p<0.001 vs. intermediate-term HDM (B,C) ap<0.05 vs. time-matched PBS control;
b

p<0.05 vs. short-term HDM; Cp<0.05 vs. intermediate-term HDM.
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Figure 7. HDM-specific IgE and IgG1 gradually increase over the course of HDM exposure. At sacrifice,
serum was collected from both naïve and HDM-exposed animals. HDM-specific (A) IgE and (B) IgG1
levels were determined via ELISA. Dual absorbance at 450 nm and 570 nm was calculated over a range
of dilutions. Data represent mean ± SEM values; n = 6-8 mice per group. For statistical purposes, group
comparisons were based on area under the curve (AUC) measurements. ap<0.01 vs. AUC of timematched PBS control; bp<0.01 vs. AUC of short-term HDM; cp<0.01 vs. AUC of intermediate-term
HDM. K, thousand; M, million.
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Figure 8. Th2 cytokines peak in the lung compartments following short-term HDM exposure. At
sacrifice, BAL supernatant was collected from PBS-exposed (unshaded bars) and HDM-exposed (shaded
bars) C57BL/6 females and concentrated ten-fold. Lung tissue homogenates and serum were collected
from PBS (short-term only) and HDM animals. Cytokine levels were determined via multiplex analysis.
Data represent mean ± SEM values; n = 5 per group (BAL), 3-4 per group (lung), 3 (serum; PBS), 9-10
per group (serum; HDM). *p<0.05, **p <0.01 vs. PBS control; †p<0.05, ††p<0.01 vs. short-term HDM; ‡
p<0.05 vs. intermediate-term HDM. L.o.D; limit of detection.
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Figure 9. HDM-exposed mice demonstrate persistent perivascular/peribronchiolar inflammation.
Formalin-fixed lungs were processed in a standard manner and stained with H&E and PAS. (Top Row;
A-D) H&E (X4, scale bar = 300 μm). Short arrows highlight examples of perivascular/peribronchiolar
inflammation. Long arrows highlight examples of smooth muscle hypertrophy. (Bottom Row; E-H) PAS
(X20, scale bar = 50 μm). Arrows highlight mucus production by airway goblet cells. (I) Inflammation
scores and (J) mucus scores were determined in a blinded fashion on a severity scale from 0-3 for PBS
control (open shapes) and HDM (closed shapes) mice. Data represent mean ± SEM values; n = 5 per
group. *p<0.05 vs. time-matched PBS control.
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Figure 10. AHR peaks following intermediate-term HDM exposure but is suppressed with long-term
HDM exposure. C57BL/6 females underwent tracheostomy and were mechanically ventilated prior to
methacholine exposure. Changes in Rrs responses to increasing doses of aerosolized methacholine were
determined using the flexiVent system (SCIREQ). Since no differences were observed within AHR
measurements for PBS control animals at 2, 5, or 11 wks, AHR data from PBS control mice were pooled
to generate a single curve (All PBS). Data represent mean ± SEM values; n =4-5 per group (HDM), 8 (All
PBS). For statistical purposes, group comparisons were based on area under the curve (AUC)
measurements. ap<0.001 vs. All PBS AUC; bp<0.001 vs. long-term HDM AUC; cp<0.01 vs. short-term
HDM AUC.
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Figure 11. Interruption of continuous HDM exposure leads to reappearance of BAL eosinophilia. Mice
were exposed to 11 wks HDM in a continuous or discontinuous manner as described in Fig 3. Briefly,
discontinuously exposed mice (Disc) were given 5 wks of continuous, i.n. HDM, after which time mice
were either rested for the duration of the 11 wk period (R-) or rested for 4 wks prior to a 2 wk HDM
rechallenge (R+). (A) At sacrifice, total leukocytes were harvested from BAL and manually counted on a
hemocytometer (B) Differentials were manually determined using cytocentrifuged preparations stained
with May-Grünwald Giemsa. Data represent mean ± SEM values; n = 5 mice per group. (A) **p<0.01
(B) ***p<0.001 vs continuous and DiscR- mice.

77

Figure 12. CD4+ T cell exhaustion does not increase in long-term HDM mice when compared to shortterm HDM mice. C57BL/6 mice were exposed to short-term or long-term HDM as shown in Fig 2, or not
exposed to Ag (naïve). (A) Sample FACS plot demonstrating gating for PD-1hi T cells among the
population of CD4+ T cells in the lung. (B) Levels of PD-1hi CD4+ T cells were calculated as a percentage
of all CD4+ T cells. Data represent mean ± SEM values; n = 6-10 mice per group. ***p<0.001 vs naïve.
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Figure 13. Foxp3+ Treg numbers increase steadily in the HLN over the course of HDM exposure and
correlate with suppression of AAD. (A) Representative flow cytometry dot plots from BAL, lung tissue,
and HLN of PBS control (short-term) and HDM-exposed C57BL/6 females. Cells were gated on
CD3+CD4+ T lymphocytes and Foxp3 expression was examined. (B) Total percentages and numbers of
Foxp3+ Tregs of all CD4+ T cells in PBS control or HDM mice. Data represent mean ± SEM values; n =
10-13 per group (PBS control; values pooled from 3 independent experiments), 15-22 per group (HDM;
values pooled from 3-5 independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001 vs. time-matched
PBS control; †††p < 0.001 vs. short-term HDM; ‡‡p<0.01, ‡‡‡ p < 0.001 vs. intermediate-term HDM.
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Figure 14. CD4+ T lymphocyte frequency in the HLN does not differ across the various stages of the
model. Total percentage of CD3+CD4+ T lymphocytes were calculated as a frequency of total, live
lymphocytes (gated on the basis of forward and side scatter) in PBS control and HDM mice. Data
represent mean ± SEM values; n = 10-13 per group (PBS control; values pooled from 3 independent
experiments), 15-22 per group (HDM; values pooled from 3-5 independent experiments).
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Figure 15. AMs assume an IL-10+ phenotype in the BAL and lung tissue following long-term HDM
exposure. Male and female Vert-x mice were subjected to short-term or long-term PBS or HDM exposure
as shown in Chapter 2, Fig 2. (A) Sample FACS plot demonstrating gating for F4/80+CD11c+ AMs
(encircled) among the population of total BAL leukocytes in short-term PBS control mouse. (B)
Representative histogram plot of IL-10-GFP expression in CD11c+ AMs. Solid, light grey-lined
histograms represent short-term Ag exposure in PBS control (unshaded) or HDM (shaded) mice. Solid,
dark grey-lined histograms represent long-term Ag exposure in PBS control (unshaded) or HDM (shaded)
mice. Dotted histogram represents negative control (GFP- AMs from a WT mouse). (C) MFI of IL-10GFP expression in CD11c+ AMs from PBS control (unshaded bars) or HDM (shaded bars) mice. Dotted
line represents negative control (GFP- AMs from a WT mouse). (D) Frequency of IL-10-GFP+
macrophages expressed as % total AMs from PBS control (unshaded bars) and HDM (shaded bars) mice.
(E) MFI of IL-10-GFP expression in CD11c- IMs from PBS control (unshaded bars) or HDM (shaded
bars) mice. Dotted line represents MFI of GFP- IMs from a WT mouse. Data represent mean ± SEM
values (combined for male and females); n = 5-6 per group (representative of three independent
experiments). *p < 0.05, ***p < 0.001 vs. time-matched PBS control; ††† vs. short-term HDM.
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Figure 16. AMs in the BAL of mice discontinuously exposed to HDM produce IL-10. MFI of IL-10-GFP
expression in CD11c+ AMs from 11 wk continuous, DiscR-, and DiscR+ mice. Dotted line represents MFI
of GFP- AMs from a WT mouse. Data represent mean ± SEM values; n = 5-6 per group, *p < 0.05, **p <
0.01, ***p < 0.001.
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CHAPTER 4
THE ROLE OF IL-10 AND ALVEOLAR MACROPHAGES IN TOLERANCE
DEVELOPMENT AGAINST HOUSE DUST MITE

Introduction
The respiratory tract is continuously subjected to a variety of innocuous Ags197. Although this
exposure commonly results in the development of immunologic tolerance or non-responsiveness against
these Ags, lack of tolerance generation can lead to allergic asthma158,198,199. Despite the magnitude of this
problem, many pharmacologic therapies for asthma are primarily geared towards symptom relief and
exert few, if any, effects on long-term disease progression200. It has become critical to dissect the
mechanisms that affect tolerance development in order to target improved therapies that can restore
normal immunity and quality of life in asthmatic patients.
Regulatory T cells (Tregs) are essential for suppressing immune responses against nonpathogenic Ags186. Due to the fact that Tregs are often decreased in asthmatic airways, methods to expand
Tregs and enhance their suppressive potential has been the focus of many recent studies59,60. However, the
mechanism by which Tregs are generated in the process of tolerance formation against inhaled allergens
has not been well established.
AMs play a key role in the defense against inhaled pathogens and allergens and can transition
between a number of functional phenotypes exhibiting opposing roles (i.e. pro-inflammatory versus antiinflammatory, immunogenic versus tolerogenic)75. Previous findings in our long-term HDM model have
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shown that suppression of AAD is associated with an accumulation of IL-10+ AMs in the BAL and lungs
of HDM-tolerant mice. These cells (traditionally thought of as “regulatory” AMs) primarily arise during
late stages of the immune response and can downregulate inflammation201 through production of antiinflammatory cytokines202,203. Although the exact mechanism by which IL-10+ AMs exert their regulatory
activities has not been described, one possibility is that they induce Foxp3+ Tregs through their secretion
of IL-10 and TGF-β, a theory that has been supported by human and mouse studies alike103,204-206.
Moreover, we have observed concurrent increases in both Foxp3+ Tregs and IL-10+ AMs at the site of
inflammation in HDM-tolerant mice (Chapter 3, Figs 13 and 15). However, while the contributions of
Foxp3+ Tregs in the suppression of asthmatic responses have been long accepted, the role of IL-10+ AMs
in tolerance against inhaled allergens has not been well-documented.
The purpose of this study was to evaluate the contribution of IL-10+ AMs to the induction of
immunologic tolerance against long-term HDM exposure. Our results demonstrated that neither IL-10 nor
IL-10+ AMs are likely to be the essential contributors to the suppression of AAD seen with long-term
HDM exposure in mice with otherwise intact immune systems. However, AMs from long-term HDM
mice showed an enhanced ability to induce Foxp3+ Tregs in vitro, suggesting that these cells do have
regulatory functions and can contribute to the overall attenuation of AAD observed in this long-term
HDM model.

Results
IL-10 was nonessential for the suppression of allergic inflammation with long-term HDM exposure
To determine whether IL-10 was required for the development of tolerance to HDM, total
leukocyte counts and cellular differentials were performed in wild type (WT) and IL-10-/- mice following
short-term or long-term HDM instillation. No differences were seen in total BAL, HLN, or lung leukocyte
counts prior to the start of HDM exposure (Fig 17A). Following short-term HDM exposure, IL-10-/- mice
trended towards increased leukocyte counts in all three lung compartments relative to WT mice, though
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these differences were not statistically significant. However, following long-term HDM exposure, WT
and IL-10-/- mice demonstrated similar leukocyte counts in the BAL, HLN, and lungs.
As expected, neither WT nor IL-10-/- mice had any evidence of BAL eosinophilia prior to HDM
exposure (Fig 17B). Following short-term HDM exposure, eosinophil levels increased to ~40-45% in
both sets of mice, but declined to <3% following long-term HDM exposure. Additionally, total IgE levels,
which were non-significantly elevated in IL-10-/- mice relative to WT mice following short-term HDM
exposure, declined significantly following long-term HDM exposure (Fig 17C). Together, these data
suggest that IL-10 is dispensable for tolerance generation and subsequent suppression of allergic
inflammation following long-term HDM exposure.

IL-10-/- animals did not demonstrate AHR with intermediate-term HDM exposure
Although airway inflammation may contribute to the development of airflow obstruction, it does
not always correlate well with pulmonary function207. To determine whether IL-10 was required for
suppression of AHR with long-term HDM exposure despite its seemingly dispensable role in suppression
of allergic inflammation, WT and IL-10-/- mice were administered HDM for short-, intermediate-, and
long-term periods prior to methacholine challenge. No differences were observed between methacholine
challenge curves of WT and IL-10-/- mice in their naïve states or after short-term HDM challenge (Fig
18). However, while WT mice showed peak AHR following intermediate-term HDM exposure, IL-10-/demonstrated a significantly decreased response with no evidence of AHR even at higher doses of
methacholine. Furthermore, while long-term HDM exposure was associated with resolution of AHR
responses in WT mice, IL-10-/- mice simply maintained their relative lack of AHR. Together, these data
suggest that while WT mice are capable of exhibiting a biphasic AHR response in response to HDM
instillation, IL-10-/- mice do not demonstrate any evidence of AHR with intermediate-term HDM
exposure.
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IL-10-/- animals had a lower frequency of local Foxp3+ Tregs upon allergen challenge than WT
animals
Since IL-10-/- mice appeared to be capable of inducing immunologic tolerance to long-term HDM
administration in a similar manner as WT mice (as demonstrated by suppression of BAL eosinophilia),
we examined percentages of Foxp3+ Tregs in the lung compartments of IL-10-/- mice to determine
whether similar increases in Treg levels were noted at tolerance as were seen in WT HLNs (Chapter 3,
Fig 13). While no differences were observed in Treg frequency in the BAL, HLN, or lung tissue of naïve
WT and IL-10-/- animals (data not shown), short-term HDM-exposed IL-10-/- mice demonstrated
significantly decreased Treg levels in the BAL and HLN when compared to WT animals (Fig 19).
Moreover, this decrease in Treg frequency was found to be significant in all three lung compartments
following long-term HDM exposure. Interestingly, while BAL and lung tissue Treg percentages were
further reduced in long-term HDM-exposed IL-10-/- mice relative to short-term HDM-exposed IL-10-/mice, HLN Tregs exhibited the opposite trend, a finding consistent with what we have previously
observed in WT animals. These data support the idea that the HLN is the most critical site for Treg
accumulation and subsequent suppression of AAD responses.

AMs from long-term HDM mice induced Foxp3+ Tregs in vitro
Despite suppression of BAL eosinophilia in IL-10-/- mice with long-term HDM exposure,
macrophages did not appear to have the same gross morphological features (i.e. were neither enlarged
when compared to naïve or short-term HDM-exposed macrophages nor multinucleated) like those seen in
WT mice following long-term HDM exposure (Chapter 3, Fig 6D, Figs 20A-C). These findings
supported the idea that the enlarged, multinucleated macrophages seen in long-term HDM-exposed WT
mice are IL-10+ cells. Since IL-10-/- mice also demonstrated decreased Treg levels when compared to WT
mice, we hypothesized that IL-10+ “regulatory” AMs may contribute to Treg induction. To test this
hypothesis, we performed Treg induction assays using AMs from short-term HDM-exposed mice, longterm HDM-exposed mice, and time-matched control (11 wks PBS) mice. Foxp3+ Treg frequency in the
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purified naïve Teff population prior to co-culture with AMs was <2%. In the absence of exogenous TGFβ, AMs did not induce Tregs in any of the groups, suggesting that AMs do not produce significant
amounts of TGF-β at any stage of the model (Fig 21A). In the presence of exogenous TGF-β, AMs from
short-term HDM mice and long-term PBS mice induced ~16-17% Tregs, a frequency that doubled when
AMs from lungs of long-term HDM mice were used as the APC. Together, these findings suggested that
long-term HDM-exposed AMs have an enhanced ability to induce Foxp3+ Tregs relative to AMs from
short-term HDM mice or time-matched PBS control mice.
To determine whether the increase in Treg induction seen with long-term HDM-exposed AMs
was the result of their enhanced IL-10 production, similar co-culture experiments were performed with
αCD3 and TGF-β in the presence or absence of neutralizing antibodies to IL-10 and IL-10R. AMs from
long-term HDM mice induced 10% more Tregs than AMs from short-term HDM mice and 5% more
Tregs than AMs from long-term PBS control mice in the presence of αCD3 and exogenous TGF-β;
however, this effect was not significantly inhibited by blockade of IL-10 and IL-10R signaling (Fig 21B).
Low-level expression of MHC II and co-stimulatory markers on APCs has been thought to enhance their
Treg- inducing abilities. When compared to PBS control animals, AMs in HDM-exposed animals
demonstrated a significant upregulation in MHC II expression (Fig 21C). However, long-term HDM
exposure resulted in a significant decline in MHC II levels on AMs relative to short-term HDM exposure,
further potentiating their regulatory capacity.

Depletion of AMs did not affect tolerance development with long-term HDM exposure
To next determine whether AMs from long-term HDM-exposed mice have an in vivo role in
tolerance induction, we depleted AMs in long-term HDM-exposed mice using intranasal injections of
Cl2MDP (clodronate) liposomes. Studies in Vert-x mice have shown that IL-10+ AMs first appear in the
BAL and lungs after intermediate-term (5 wks) HDM exposure, as was demonstrated by a rightward shift
in the GFP expression curve (Fig 22A) representing significantly increased MFI of IL-10 in CD11c+ AMs
relative to PBS control animals (Fig 22B). Intermediate-term HDM-exposed Vert-x mice also showed a
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significantly increased percentage of IL-10+ AMs relative to control animals (Fig 22C) that appeared
before the period when eosinophilia has been shown to resolve (~7-8 weeks). Thus, the AM depletion
protocol shown in Chapter 2, Fig 4 was devised to (more specifically) deplete IL-10+ AMs.
Weekly, intranasal administration of Cl2MDP to either i.n. PBS- or HDM-exposed resulted in 8085% depletion of AMs in both the BAL and the lungs (Fig 23A). To next test the hypothesis that AM
depletion would prevent suppression of allergic inflammation with long-term HDM exposure, we
attempted to determine eosinophil frequencies in the airways of Cl2MDP-treated mice but were unable to
manually perform cellular counts and differentials due to widespread AM death. However, FACS analysis
demonstrated that variable percentages of Siglec-F+CD11b+CD11c- eosinophils were present in the BAL
of HDM-exposed, Cl2MDP-treated animals but not animals administered control liposomes (data not
shown). This suggested that depletion of AMs after intermediate-term HDM exposure may have inhibited
generation of tolerance to long-term HDM; however, this could not be reliably confirmed through
assessment of inflammatory parameters due to the limitations described above.
To better test the hypothesis that AMs are involved in generation of tolerance to HDM, Cl2MDPor control-treated mice that were exposed to long-term, i.n. PBS or HDM were subjected to methacholine
challenge to determine whether AM depletion inhibited suppression of AHR responses in HDM-instilled
animals. As expected, long-term PBS and HDM mice administered control liposomes showed no
evidence of AHR (Fig 23B). Interestingly, Cl2MDP treatment did not alter AHR responses in either PBS
control or HDM mice, suggesting that AMs do not play a critical role in suppression of AAD with longterm HDM exposure.

In vivo AM depletion did not affect Foxp3+ Tregs in the HLN
In order to examine the question of whether IL-10+ AMs influence Foxp3+ Treg induction in vivo,
Treg frequencies were examined in the HLNs of long-term HDM-exposed mice after Cl2MDP liposome
administration. PBS control mice had similar levels of Tregs in the HLN regardless of whether they were
given Cl2MDP or control liposomes (Fig 24A). HDM mice demonstrated comparable levels of HLN
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Tregs as PBS control animals regardless of liposome treatment type, indicating that AMs do not much
influence accumulation of Tregs in the HLN in long-term HDM mice.
Because AMs are not thought to migrate to the HLN in significant numbers, we wanted to
determine whether regulatory interactions can occur between AMs and CD4+ T cells in the lung. Confocal
imaging of lung sections from long-term HDM-exposed mice revealed clusters of inflammatory cells
surrounding Epcam+ airway epithelial cells (Fig 24B) that had previously been appreciated on H&E
staining (Chapter 3, Fig 9D). These clusters were primarily comprised of F4/80+CD11c- IMs and CD4+ T
cells, which were found to be in close proximity to one another. On the other hand, F4/80+CD11c+ AMs
(purple) were located diffusely throughout the alveoli and showed minimal interactions with CD4+ T cell
clusters in the lung. Together, these data suggest that AMs are not likely to influence Treg induction in
the lung tissue in a contact-dependent manner.

Discussion
Alveolar macrophages (AM) have been termed “the forgotten cell in asthma”208 because despite
their importance for maintaining homeostasis in the lung, their anti-inflammatory functions have not been
extensively characterized. The present findings demonstrate that IL-10+AMs, which were generated
following intermediate-term HDM exposure and maintained in the BAL and lungs of HDM-tolerant
animals (Chapter 3), had regulatory properties and were capable of inducing Foxp3+ Tregs in vitro.
However, these macrophages appeared to have a non-essential role in tolerance generation against HDM
in vivo.
IL-10 is well known for its ability to dampen excessive inflammatory responses and is thought to
play a role in the maintenance of tolerance against inhaled allergens. However, its critical function in the
induction of tolerance has, to the best of our knowledge, not definitely been demonstrated. When WT and
IL-10-/- animals were administered i.n. HDM, both developed AAD at similar severities following shortterm allergen exposure, as demonstrated by comparable leukocyte counts, eosinophil levels, and nonsignificant differences in total IgE levels. However, with long-term HDM exposure, IL-10-/- mice were
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capable of developing immune tolerance to the same degree if not better than WT mice, as was
demonstrated by their significantly reduced total serum IgE levels. These data are in agreement with
previous findings from our laboratory, which have shown that IL-10 is non-essential for the formation of
tolerance in our OVA model209. Although suppression of airway inflammation in our HDM model was
not affected by loss of IL-10, the influence of IL-10 on resolution of AHR could not be evaluated since
IL-10-deficient mice did not develop AHR upon intermediate-term HDM exposure. Other groups have
also demonstrated lack of AHR upon methacholine challenge in IL-10-/- animals despite the fact that Th2
inflammatory responses are not inhibited194,210,211. Moreover, this protective phenotype can be 1) disrupted
if IL-10 is reconstituted in IL-10-/- mice and 2) transferred if splenocytes from allergen-sensitized IL-10-/mice are injected into sensitized SCID mice prior to allergen challenge211. Although the mechanism
behind this protection in not entirely understood, it has been suggested that IL-10-/- mice have increased
IL-13Rα2, a decoy receptor for IL-13194. Collaboration between these two molecules is likely responsible
for the phenotype observed in IL-10-/- mice following allergen sensitization and challenge, with IL-10
functioning as the dominant inhibitor of Th2 inflammation and IL-13Rα2 as a key inhibitor of AHR and
mucus hypersecretion.
Given the aforementioned results, it would seem likely that IL-10 acts as a double-edged sword in
the suppression of AAD seen with long-term HDM exposure. While its suppressive effects on allergic
airway inflammation are well-documented, the mechanism by which IL-10 facilitates development of
AHR is not known. However, it must act in concert with one or more inflammatory factors to increase
smooth muscle reactivity because AHR has not been observed naïve, IL-10-competent animals. In
addition, administration of IL-10 alone in WT mice has not been shown to augment AHR212. Thus, the
biphasic AHR response observed in intermediate-term HDM mice and long-term HDM mice despite the
presence of IL-10+ AMs in the lungs of both groups is likely to hinge on the absence of a key
inflammatory mediator in the latter set. Follow-up studies should be done to identify this factor, although
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we have shown that IL-13 does not decrease with long-term HDM exposure and that IL-17 is not
detectable across any stage of the model (data not shown).
Despite suppression of allergic inflammation in IL-10-/- mice with long-term HDM exposure,
“regulatory” AMs were not thought to develop in these animals, as they did not bear any gross
resemblance to the macrophages observed in the BAL of long-term HDM-exposed WT mice.
Unfortunately, we were unable to test this hypothesis by FACS analysis since IL-10 was used as the
defining marker of these anti-inflammatory cells. Thus, additional studies should be performed to better
characterize these macrophages in WT mice so that other reliable phenotypic markers of these AMs can
be identified. Yet what was most intriguing was that although long-term HDM-exposed WT and IL-10-/mice both displayed similar tolerogenic phenotypes, Foxp3+ Tregs were reduced in the BAL, lung, and
HLN of IL-10-/- mice relative to their WT counterparts, suggesting a critical role for IL-10 in the
induction and/or maintenance of Foxp3+ Tregs. Both functions of IL-10 have been previously
demonstrated by other groups104,105; however, Denning et al. were among the few who have shown an
essential role for IL-10/IL-10R signaling in the Ag-specific generation of Foxp3+ Tregs. In fact, one of
the most interesting observations made by the Pulendran laboratory was that lamina propria macrophages
were the primary source of the IL-10 required for Treg generation104 and were more efficient in inducing
Tregs than lamina propria DCs in the presence of exogenous TGF-β. Naïve AMs and lung-resident
macrophages are other examples of mucosal M2 macrophages capable of inducing Foxp3+ Tregs and do
so in a TGF-β- and retinoic acid-dependent but IL-10-independent manner 98,103. In contrast with the work
by Coleman et al. and Soroosh et al., we did not find that our AMs were able to produce significant
amounts of TGF-β, suggesting that these cells transition to a different subtype of macrophage (either M1
or TGF-β- M2 cells) once they are exposed to allergens. However, it was clearly evident that in the
presence of exogenous TGF-β, IL-10+ AMs from the lungs of long-term HDM mice were capable of
inducing a greater percentage of Foxp3+ Tregs than IL-10- AMs from short-term HDM mice. This is
likely explained by the fact that short-term HDM exposure upregulates macrophage production of M1
cytokines (IL-1, IL-6, TNFα)103, MHC II, and co-stimulatory markers, thus inhibiting their ability to
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effectively generate Treg cells. We have shown that with long-term HDM exposure, AMs regain their
ability to generate Tregs, perhaps by altering their surface marker and cytokine profile to a more antiinflammatory nature. Along these lines, the fact that AMs from long-term HDM mice did not consistently
induce more Tregs than long-term PBS-exposed AMs can be attributed to the low activation status (e.g.
low MHC II levels) of the latter population.
Unlike the study conducted by Denning et al., IL-10/IL-10R signaling did not appear to have a
significant role in AM-mediated induction of Tregs. However, inhibiting this signaling pathway was
associated with trending decreases in Treg induction in all three experimental groups. A more significant
inhibition on Treg induction may have been noted if a greater concentration of anti-IL-10 and anti-IL-10R
antibody had been used; in fact, the results from Denning et al. suggest that at least twice as much anti-IL10 and anti-IL-10R are recommended104. Thus, our studies should be repeated with larger doses of
neutralizing antibodies. However, other potential targets should also be considered when accounting for
the ability of long-term HDM AMs to induce more Tregs than AMs from short-term HDM mice,
including retinoic acid (see Chapter 6, Future Directions).
In order to study the in vivo relevance of AMs in tolerance formation against HDM, clodronate
liposomes were administered i.n. to long-term HDM-exposed mice, which depleted over 80% of AMs in
the BAL and lungs. While we lacked the ability to specifically deplete IL-10+ macrophages within these
studies, we attempted to work around this issue by administering clodronate liposomes specifically during
the critical period when these cells appear and tolerance begins to form (weeks 5-9). Depletion of AMs
during this critical period did not prevent the suppression of AHR associated with long-term HDM
exposure, suggesting that AMs are not essential for development of immunologic tolerance to HDM. This
contrasts with previous studies, which have shown that AMs from allergy-resistant animals protect
against the development of AHR92. However, this may be explained by the fact that we likely depleted
both pro- and anti-inflammatory AM populations with clodronate liposome administration during weeks
5-9. Thus, it is difficult to determine whether the depletion of pro- and anti-inflammatory AMs negated
the protective effects of IL-10+ AMs on AHR or whether AMs truly lack a protective role in this model.
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Long-term HDM exposure and subsequent development of tolerance is associated with increases
in regulatory lymphocytes within the HLN (Chapter 3), which we have previously shown can attenuate
severity of AAD when adoptively transferred into RAG-/- mice prior to allergen challenge150. Although
AMs were capable of inducing Tregs in vitro, depletion of AMs did not reduce Treg frequency in the
HLN, demonstrating that these cells may not impact induction of Tregs within this critical site of immune
regulation. Although AMs do have the capacity to migrate to the HLN213, studies have shown that transfer
of Ag-pulsed lung macrophages to lymphotoxin β receptor-deficient mice that do not possess peripheral
lymph nodes does not inhibit the ability of these cells to induce iTregs103. This supports our finding that
AMs do not have an obligate role in promoting HLN Treg generation. However, the one caveat in these
data was the fact that long-term HDM mice administered control liposomes did not demonstrate increased
Tregs over time-matched PBS control mice as was expected based on results described in Chapter 3.
However, the fact that these HDM-instilled, control liposome-treated mice demonstrated suppression of
AHR responses despite lack of Treg increases in the HLN raises the additional question of how critical
Tregs truly are to this overall process.
Ag-pulsed lung macrophages transferred intratracheally into naïve, immune-competent mice in
conjunction with naïve Foxp3- Ag-specific T cells have been shown to convert a significant percentage of
these T cells to Foxp3+ iTregs within the lungs103. We have previously demonstrated that Foxp3+ Tregs
increase in the lungs of HDM-exposed animals relative to PBS controls at all time points, suggesting that
HDM exposure leads to Treg induction in the lungs. However, no specific increases in Tregs were
previously observed in the lungs of long-term HDM mice relative to short-term or intermediate-term
HDM mice. If Tregs are indeed generated at a greater frequency by HDM-tolerant AMs in vivo, it is
possible that the newly induced cells may migrate immediately to the HLN, where they slowly
accumulate over time to eventually dampen Th2 responses (Chapter 3, Fig 13). Nevertheless, it is
important to note that if this phenomenon does indeed occur, AMs likely play an ancillary role in this
process, as they were unable to produce TGF-β and demonstrated minimal cell-cell contact with T cells in
the lung.
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In conclusion, the present study demonstrated a non-essential role for IL-10 and IL-10+ AMs in
tolerance generation against long-term HDM. Nevertheless, IL-10+ AMs from HDM-tolerant mice were
shown to have an enhanced capacity to convert naïve Teff to Foxp3+ iTregs in vitro, the first data of its
kind to demonstrate that allergen-exposed AMs regain their ability to induce Tregs if Ag exposure
persists for a chronic and continuous period of time. These data imply that AMs from long-term HDM
mice are truly regulatory cells; however, their contributory effects may be masked by a plethora of
additional regulatory mechanisms that can compensate for their absence in vivo. This redundancy in
compensatory mechanisms may explain why the vast majority of people do not develop allergic responses
upon exposure to inhaled allergens. A combination of regulatory deficits (including lack of IL-10+ AM
development) may in fact be required to induce an asthmatic response. Thus, additional studies on the
utility of IL-10+ AMs to skew the immune system towards a regulatory response are certainly warranted.
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Figures

Figure 17. IL-10 is not critical for suppression of eosinophilic inflammation in response to long-term
HDM exposure. Female IL-10-/- or WT (C57BL/6) mice were exposed i.n. HDM extract for up to 2 or 11
wks as described in Chapter 2, Fig 2. (A) At sacrifice, leukocytes from BAL, HLN, and lungs were
harvested and manually counted on a hemocytometer. (B) Cytocentrifuged BAL cell preparations were
stained with May-Grünwald Giemsa and differential analysis was manually performed. (C) Total serum
IgE levels were determined via ELISA. Statistical comparisons were made between WT and IL-10-/- mice.
*p<0.05

97

Figure 18. IL-10-/- mice do not exhibit AHR in response to intermediate-term HDM exposure. Female
WT (dotted lines) or IL-10-/- (solid lines) mice underwent tracheostomy and were mechanically ventilated
prior to methacholine exposure. Changes in Rrs responses to increasing doses of aerosolized
methacholine were determined using the flexiVent system (SCIREQ). Data represent mean ± SEM
values; n =5 per group. For statistical purposes, group comparisons were based on area under the curve
(AUC) measurements.
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Figure 19. Foxp3+ Treg numbers are significantly decreased in the lung compartments of HDM-exposed
IL-10-/- mice relative to WT mice. Total percentages of Foxp3+ Tregs of all CD4+ T cells in WT and IL10-/- mice subjected to either 2 or 11 wks of i.n. HDM. Data represent mean ± SEM values; n = 4-5 per
group. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 20. Macrophages do not become enlarged and multinucleated in IL-10-/- mice administered longterm HDM. (A) Naïve, female IL-10-/- mice were exposed to i.n. HDM extract for either (B) 2 wks or (C)
11 wks as described in Chapter 2, Fig 2. At sacrifice, total BAL leukocytes were harvested and
cytocentrifuged preparations were stained with May-Grünwald Giemsa. 20X magnification.
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Figure 21. AMs from long-term HDM-exposed mice induce Foxp3+ Tregs in the presence of exogenous
TGF-β. (A) AMs isolated from the lungs (6-7 lungs pooled per group) of short-term HDM, long-term
PBS, or long-term HDM were isolated at a 1:1 ratio with naïve Teff (isolated from the spleens of naïve
Foxp3gfp mice) in the presence of αCD3 ± TGF-β for 72 hours. Plots represent frequency of GFPexpressing (Foxp3+) Tregs of all Teff. (B) Similar co-cultures were repeated in the presence of αCD3 and
TGF-β ± αIL-10 and αIL-10R neutralizing antibodies (2 lungs pooled per sample, n = 3-4 samples per
group). Unshaded bars represent samples without αIL-10/IL-10R blockade and shaded bars represent
samples with αIL-10 and αIL-10R blockade. (C) MFI of MHCII on sorted AMs from (B) prior to coculture. *p<0.05, **p<0.01, ***p<0.001
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Figure 22. AMs assume an IL-10+ phenotype in the BAL and lung tissue following intermediate-term
HDM exposure. Male and female Vert-x mice were subjected to intermediate-term (5 wks) PBS or HDM
exposure as shown in Chapter 2, Fig 2. (A) Representative histogram plot of IL-10-GFP expression in
CD11c+ AMs from PBS control (unshaded) or HDM (shaded) mice. (B) MFI of IL-10-GFP expression in
CD11c+ AMs from PBS control or HDM mice. Dotted line represents negative control (GFP- AMs from a
WT mouse). (C) Frequency of IL-10-GFP+ macrophages expressed as % total AMs from PBS control and
HDM mice. Data represent mean ± SEM values (combined for male and females); n = 5-7 per group.
***p < 0.001
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Figure 23. AM depletion does not deter tolerance formation against HDM with long-term exposure. Mice
receiving either long-term i.n. PBS or HDM were administered control or clodronate liposomes to deplete
AMs as shown in Chapter 2, Fig 4. (A) Representative plots of AM depletion efficacy in live, CD45+ cell
populations in BAL and lungs of PBS- and HDM-instilled mice. (B) Mice were tracheostomized,
mechanically ventilated, and subjected to methacholine challenge. Changes in Rrs responses to increasing
doses of aerosolized methacholine were determined using the flexiVent system (SCIREQ). Data represent
mean ± SEM values; n =5 per group. For statistical purposes, group comparisons were based on area
under the curve (AUC) measurements. No statistical differences were observed.
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Figure 24. Long-term HDM-exposed AMs do not influence Foxp3+ Treg generation in the HLN or lung
tissue. (A) Long-term HDM or PBS mice were subjected to Cl2MDP or control liposome treatment as
described in Chapter 2, Fig 4. Total percentages of HLN Foxp3+ Tregs of all CD4+ T cells were
determined. Data represent mean ± SEM values; n = 5 per group. No statistical differences were found
between groups. (B) Lung tissue sections (n=2) from long-term HDM mice stained with fluorescentlyconjugated antibodies were examined via confocal microscopy. A representative image is shown above.
10X magnification.
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CHAPTER 5
DEVELOPING A MURINE MODEL OF ALLERGEN-SPECIFIC IMMUNOTHERAPY
FOR THE TREATMENT OF HOUSE DUST MITE-INDUCED ASTHMA

Introduction
Allergic asthma is a chronic lung disorder that affects 300 million people worldwide. Annual
healthcare expenditures for asthma exceed $50 billion, yet current pharmacologic agents for asthma are
primarily directed at symptom relief and have limited curative potential and poor prospects for reducing
disease prevalence. Allergen-specific immunotherapy (ASIT) is currently the only etiologic therapy for
treatment of atopic disorders. By altering the immune response to the triggering allergen, ASIT has been
shown to provide long-lasting relief of disease symptoms and improve quality of life in asthma patients.
Although the detailed mechanisms by which ASIT exerts its effects are actively being investigated, most
studies have been conducted in humans and thus have been unable to evaluate the specific immunologic
and physiologic consequences of ASIT within the lungs. Moreover, the few murine models of ASIT for
treatment of allergic asthma have been conducted using human-irrelevant allergens such as OVA. Our
limited understanding of the mechanisms underlying the effects of ASIT has been a barrier to the
development of evidence-based clinical practice guidelines and universally effective ASIT for asthma.
Evidence supports the role of peripheral Foxp3+ Tregs in the clinical efficacy of ASIT128,214-218,
although the mechanism by which these Tregs are induced in asthmatic patients who have successfully
undergone ASIT is not well-characterized. Clinical trials have demonstrated that ASIT increases IL-10
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production by peripheral monocytes and local macrophages, as was shown in nasal biopsies of patients
with seasonal rhinitis129,130. However, the contribution of IL-10+ alveolar macrophages (AMs) in patients
with asthma has not previously been examined since the site of inflammation (i.e. lung compartments), as
mentioned above, cannot be easily accessed in human subjects. Our laboratory has previously shown that
AMs from HDM-tolerant mice that produce high levels of IL-10 are capable of inducing Foxp3+ Tregs in
vitro (Chapter 4, Fig 21). However, the contribution of these cells to ASIT and their role on local Foxp3+
Treg induction in the context of HDM-ASIT are not currently known.
The goal of this study was to develop a clinically-relevant murine model to investigate both the
specific effects of ASIT on HDM-induced AAD and the potential role of IL-10+ AMs in mediating the
clinical benefits of ASIT. Results from this study suggest that biweekly, subcutaneous ASIT with a
standardized HDM extract following development of AAD attenuates severity of AAD, with specific
reductions in airway eosinophilia, perivascular/peribronchiolar lung inflammation, mucus production, and
Th2 cells. However, these clinical benefits of ASIT appeared to occur independently of specific increases
in Foxp3+ Tregs or IL-10+ AMs at the site of inflammation.

Results
Short-term ASIT was unable to reproducibly decrease eosinophil frequency in HDM-exposed mice
In order to determine whether ASIT attenuates severity of HDM-induced AAD, short-term HDM
mice were administered subcutaneous ASIT with a standardized HDM extract biweekly for 3 weeks at
either a low dose or high dose while continuing to receive i.n. HDM (Chapter 2, Fig 5A). No adverse
reactions in response to ASIT were noted in any mice for the duration of the study.
Although ASIT did not reduce total number of leukocytes in the BAL relative to mice receiving
control animals, BAL eosinophil frequency was attenuated in a dose-dependent manner (Fig 25A) with
compensatory increases in macrophage frequency (Fig 25B). However, when these protocols were tried
three additional times, no effect of low dose or high dose ASIT on BAL eosinophils was observed,
suggesting that short-term ASIT does not reliably attenuate AAD.
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Long-term ASIT reduced BAL eosinophilia in HDM-exposed animals
A possible reason why short-term ASIT was not able to repeatedly attenuate AAD is because
mice may not adequately develop tolerance to HDM with only six ASIT injections; longer courses of
ASIT are likely required for this effect to occur. In order to afford more ASIT injections without risking
spontaneous development of tolerance with continuous, intranasal HDM exposure, a DiscR+ HDM model
was utilized (Chapter 2, Fig 3) in which mice are rested and rechallenged to prevent full resolution of
BAL eosinophilia (Chapter 3, Fig 11A). This long-term model of ASIT is shown in Chapter 2, Figure 5B.
Both low and high-dose ASIT significantly reduced total leukocyte counts (55% reduction; Fig
26A) in the BAL relative to HDM-Control animals. Non-significant reductions in total leukocyte counts
were also observed in the lung with low-dose ASIT (21% reduction) and high-dose ASIT (49%
reduction), however, reductions in total HLN leukocytes were only observed with high-dose (41%
reduction) and not low-dose ASIT (Fig 26A).
In addition to total leukocyte counts, both low- and high-dose ASIT were associated with similar
reductions in frequency (~45% reduction; Fig 26B) and number (~75% reduction; Fig 26C) of
eosinophils in the BAL relative to control animals. Although these reductions were non-significant, it is
likely that these findings would be statistically significant if group sizes were increased. Macrophage
morphology (e.g. frequency of multinucleated cells) was not noted to be significantly altered with ASIT
(data not shown) despite the fact that compensatory increases in macrophages were also noted with ASIT
(Fig 26B).

ASIT attenuated inflammation and mucus production in the lungs of HDM-exposed animals
In HDM-Control mice, large perivascular and peribronchiolar inflammatory clusters were noted
diffusely throughout the lungs and averaged from 3-5 in number per 10X field (Fig 27A; top left). ASIT
reduced both the size and number of these clusters per 10X field, with low-dose ASIT (Fig 27A; top
center) having a greater effect than high-dose ASIT (Fig 27A; top right). Nevertheless, both low-dose
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ASIT and high-dose ASIT showed significantly reduced inflammation scores compared to control mice
when blindly scored (Fig 27B).
A large percentage of airways in HDM-Control mice contained ring-like structures of PASpositive cells, suggesting exacerbated mucus production (Fig 27A; bottom left). Although several of these
PAS-positive ring-like structures were also seen in the airways of low dose ASIT mice, their frequency
was greatly diminished (Fig 27A; bottom center). Intriguingly, high dose ASIT mice showed an even
further reduction in frequency of PAS-positive airways, with the majority of these airways consisting of
punctate PAS staining rather than full ring-like structures (Fig 27A; bottom right). Although blinded
scoring results did not support a significant decrease in mucus production in the airways of high dose
ASIT mice relative to HDM-Control mice (Fig 27C), this trend was certainly noticeable on histology.
Together, these findings suggest that subcutaneous ASIT decreases both inflammation and mucus
production in the lungs, with low-dose ASIT having a drastic effect on number and size of inflammatory
clusters and high-dose ASIT more greatly affecting mucus production.

ASIT attenuated serum IgE levels in HDM-exposed animals
As expected, serum IgE levels were comparably elevated across groups after short-term HDM
instillation and before initiation of ASIT (Fig 28). In HDM-Control animals, DiscR+ administration of i.n.
HDM was associated with a mean 10-fold increase in IgE levels over the 11 week time course (pre- vs
post- ASIT), although the variation in IgE levels between mice was quite high. Total IgE levels were
greatly attenuated with high-dose ASIT, as they were only 2.5-fold higher at the end of the 11 week
course of i.n. HDM than in pre-ASIT mice. This effect was even more pronounced with low-dose ASIT;
in these mice, IgE levels post ASIT were only 1.1-fold higher than levels pre-ASIT. Although it should be
noted that the IgE levels observed in low-dose and high-dose ASIT mice were not significantly different
from HDM-Control animals due both to small group sizes and high variability in the control group, these
levels were 73% and 35% reduced, respectively, post-ASIT.

108

ASIT attenuated AAD-associated inflammation but did not affect AHR
In order to determine whether the reduction in inflammation associated with ASIT affected AHR,
mice were subjected to methacholine challenge and lung resistance values were determined. No
differences were observed between resistance curves of HDM-Control, HDM-Low Dose, and HDM-High
Dose mice following long-term ASIT (Fig 29A). However, even HDM-Control animals did not
demonstrate significant AHR with higher doses of methacholine, suggesting that the reduction in AHR
associated with continuous, long-term HDM exposure (Chapter 3, Fig 10) begins prior to 11 weeks and
can be observed in DiscR+ animals as well. Thus, in order to determine whether AHR is truly affected by
ASIT, similar studies were conducted in short-term ASIT mice after 5 weeks of i.n. HDM exposure, when
AHR has been shown to peak (Fig 10). Although HDM-Control animals did demonstrate AHR as
expected, neither low-dose ASIT nor high-dose ASIT was able to attenuate these AHR responses (Fig
29B), suggesting that short-term ASIT is not sufficient to improve pulmonary function.

ASIT attenuated Th2-associated inflammation but did not affect regulatory leukocyte populations
Decreased BAL eosinophilia and IgE titers suggested that ASIT may reduce Th2-based
inflammatory responses. In order to determine this, frequency of T1-ST2+ (IL-33R; a marker of Th2 cells
that is important for their effector function219) CD4 T cells in the lung tissue was examined. ASIT was
associated with dose-dependent decreases in Th2 frequency and number that was significantly attenuated
relative to HDM-Control animals with high-dose ASIT (Fig 30). This suggests that a major mechanism
by which ASIT may attenuate AAD is via reductions in Th2 effector cells, a major player in HDMinduced asthma.
Another mechanism by which ASIT has been thought to benefit patients with asthma is by
skewing the balance between effector and regulatory cells in favor of the latter. Surprisingly, no
differences were observed in levels of Foxp3+ Tregs in either the lung, HLN, or blood of low-dose or
high-dose ASIT animals relative to HDM-Control animals (Fig 31A) despite the fact that these cells have
been associated with the development of tolerance to long-term HDM exposure (Chapter 3, Fig 13). The
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appearance of IL-10+ AMs in the BAL and lung have also been associated with development of tolerance
to long-term HDM exposure (Chapter 3, Fig 15). Although some production of IL-10 in AMs was
observed in all three groups following DiscR+ exposure as was previously observed (Chapter 3, Fig 16),
no increases in IL-10 production by AMs was noted with either low-dose or high-dose ASIT (Fig 31B),
suggesting that these cells do not play a significant role in the attenuation of allergic asthma following
ASIT.

Discussion
Despite the fact that ASIT has been utilized for over a century, the mechanisms by which
subcutaneous therapy benefits patients with asthma remain incompletely understood. This lack of
knowledge is reflected by the large variety of ASIT protocols, significant variability in patient responses
to ASIT, and the overall hesitance of many clinicians to even recommend ASIT to their asthmatic
patients. To better understand the mechanisms of ASIT, we developed and characterized a clinicallyrelevant murine model of both short-term and long-term ASIT for treatment of HDM-induced allergic
airway disease. For these studies, we utilized a standardized HDM extract that is currently administered to
asthma patients in the University of Connecticut Health Center ENT clinic.
Previous studies in murine models of subcutaneous ASIT have demonstrated that ASIT
suppresses cardinal features of chronic AAD, including airway eosinophilia, Th2 cytokine production,
IgE titers, lung inflammation and airway mucus production122. Although we observed mild attenuation in
BAL eosinophil frequency with short-term ASIT, this finding was not repeatable during future studies
and encouraged us to switch to a long-term ASIT model since the clinical efficacy of ASIT has been
shown to correlate with duration of therapy117,220. Mice subjected to our long-term ASIT protocol
experienced many of the aforementioned benefits, although the magnitude of individual effects was often
dependent on the dosage of extract administered. A finding of particular interest was the fact that low
dose ASIT seemed to suppress perivascular/peribronchiolar lung inflammation on H&E when compared
to high dose ASIT, although high dose ASIT reduced total cell counts in all three lung compartments to a
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greater extent than low dose ASIT. High dose ASIT was also associated with greater effects on mucus
production than low dose ASIT, although the latter showed greater suppressive effects on serum IgE
levels. The reasons for these particular dose effects are not well understood, as few studies have delved
into the effects of ASIT dose on clinical responses (typically the maximum tolerated dose is administered
in humans). However, it is surely appreciated that ASIT outcomes are time- and dose-dependent221,221, and
it has certainly been shown that low-dose ASIT has a more beneficial effect on IgE levels during longterm protocols than high-dose ASIT222. In the clinic, ASIT dosing is decided on the basis of wheal
responses following skin prick tests, which are difficult to accurately perform in mice. The high dose
ASIT protocol utilized in this study (200 AU/injection; 1600 AU/month) was representative of the highest
dose administered to patients in the University of Connecticut Health Center ENT clinic, while the low
dose ASIT protocol (10 AU/injection; 80 AU/month) was more typical of doses administered to the
average patient. However, safety and tolerability studies with high doses of HDM ASIT have shown that
85% of HDM-allergic patients can tolerate maintenance dosages of up to 40,000 AU/month with only
grade 1 safety issues223. Thus, in the future, it would be interesting to determine whether higher doses of
HDM ASIT using our long-term protocol would be associated with more significant or more repeatable
outcomes.
Although long-term ASIT was associated with reductions in many immunological parameters,
including airway mucus and Th2 cell numbers, we were surprised to find that ASIT did not have an effect
on AHR, as has previously been observed in other murine studies using OVA-ASIT122. This was, in part,
due to the fact that HDM-Control mice in the long-term ASIT studies did not have significant AHR
responses despite high levels of lung inflammation, and so it would have been difficult to further reduce
lung resistance in experimental mice. Thus, follow-up AHR studies were done in mice receiving shortterm ASIT so that AHR could be examined at the peak of response in HDM-Control mice. Although
HDM-Control mice did show evidence of AHR at this time point, neither low nor high dose ASIT was
able to reduce this response. Although this may have been attributed to the poor repeatability of beneficial
immunological outcomes in our short-term ASIT protocol, it is more likely that the duration of ASIT was
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not long enough to observe an effect on AHR using the short-term protocol, as a minimum of 8 injections
appears to be necessary for a reduction in AHR in mice challenged with human-relevant (i.e. adjuvantcontaining) allergens222. Murine studies that provide ASIT with extremely large (>1 mg) doses of OVA
without the addition of exogenous adjuvants122 are more likely to tolerize subjects more effectively and in
a shorter time frame than ASIT studies in which HDM extract is used. Moreover, this is one of the major
reasons why ASIT requires many months to years to show clinical benefits in human subjects. Thus,
future studies should be focused on either increasing the number of ASIT injections during the short-term
protocol or challenging mice with fewer i.n. HDM injections during the long-term protocol to avoid
downregulation of AHR responses in HDM-Control mice.
One of the major mechanisms by which ASIT is thought to benefit allergic/asthmatic patients is
through induction of regulatory leukocyte populations, particularly Tregs. Interestingly, frequency of
Foxp3+ Tregs did not increase in either the lung (e.g. lung tissue, HLN) or systemic (e.g. blood)
compartments with ASIT. This was surprising, given that ASIT is frequently associated with elevated
Tregs patients who have successfully undergone this therapy124,125 and in most mouse models of ASIT
that have observed similar effects on inflammatory hallmarks of asthma122,123,224. Moreover, we have
shown that tolerance to HDM is associated with an increase in HLN Foxp3+ Tregs (Chapter 3), and
studies in mouse models of OVA-ASIT have also shown this increase to occur specifically in the local
lymph node122. However, murine studies have shown that depletion of Tregs at the time of ASIT
treatment reverses the beneficial effects on AHR but not on BAL eosinophilia or serum IgE levels,
suggesting that ASIT-mediated tolerance induction requires Foxp3+ Tregs for suppression of AHR but not
suppression of airway inflammation. Since ASIT did not significantly suppress AHR responses in our
model, this may explain why Foxp3+ Tregs were not elevated in mice that received either low- or highdose ASIT relative to control animals. Nevertheless, ASIT was still able to mediate many of its benefits
without specific increases in Foxp3+ Tregs in this model. Other studies have shown IL-10+ regulatory T
cells to be more important for mediating the benefits of ASIT122,127 While we have not currently examined
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the involvement of Tr1 cells within the context of our model, future directions will include studying this
Foxp3- regulatory subset.
In addition to an increase in IL-10 production by T cells, it has been shown that ASIT also
increases IL-10 production by peripheral monocytes and local (nasal) macrophages in patients with
seasonal rhinitis129,130. In the present study, subcutaneous ASIT did not promote increases in IL-10
production by AMs, suggesting that these cells are not directly involved in ASIT-mediated peripheral
tolerance or in the in vivo conversion of T cells to regulatory subsets. This correlates with our previous
data, which failed to show a critical role for these cells in the induction of peripheral tolerance against
HDM despite their presence in the BAL and lungs of HDM-tolerant mice.
Herein, we describe the first clinically-relevant murine model of subcutaneous ASIT for
treatment of HDM-induced asthma. Results from this study demonstrate that subcutaneous ASIT
attenuates severity of AAD by affecting multiple parameters of allergic inflammation, including total
WBC counts in the lung compartments, BAL eosinophilia, lung inflammation, mucus production, IgE
responses, and Th2 cell frequency. Further evaluation of this model may yield valuable insight into the
clinical mechanisms of ASIT, which may in turn be applied to develop safer, more effective ASIT
protocols.
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Figures

Figure 25. BAL eosinophilia associated with i.n. HDM exposure is reduced by short-term ASIT in a
dose-dependent manner. Female C57BL/6 mice were administered i.n. HDM and subjected to short-term
ASIT as described in Chapter 2, Fig 5A. Cytocentrifuged preparations of BAL cells were stained with
May-Grünwald Giemsa and differential analysis was manually performed for frequency of (A)
eosinophils and (B) macrophages. Dotted line represents mean values from HDM-Control mice that
received 5 weeks of i.n. HDM and 6 ASIT injections in a time-matched manner. Data represent mean ±
SEM values; n = 3 per group.
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Figure 26. BAL eosinophilia associated with i.n. HDM exposure is attenuated by long-term ASIT.
Female Vert-x mice were administered i.n. HDM and subjected to long-term ASIT as described in
Chapter 2, Fig 5B. (A) At sacrifice, total BAL leukocytes were harvested and manually counted on a
hemocytometer. (B-C) Cytocentrifuged preparations were stained with May-Grünwald Giemsa and
differential analysis was manually performed. Data represent mean ± SEM values; n = 5 per group.
*p<0.05 vs. HDM-Control.
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Figure 27. Long-term ASIT attenuates lung inflammation and mucus production associated with i.n.
HDM exposure. Formalin-fixed lungs were processed in a standard manner and stained with H&E and
PAS. (Top Row; A) H&E (X10). Arrows highlight examples of perivascular/peribronchiolar
inflammation. (Bottom Row; A) PAS (X10). Arrows highlight mucus production by airway goblet cells.
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(B) Inflammation scores and (C) mucus scores were determined in a blinded fashion on a severity scale
from 0-3. Data represent mean ± SEM values; n = 10 per group. *p<0.05, ***p<0.001 vs. time-matched
PBS control.
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Figure 28. Long-term ASIT following short-term HDM exposure prevents further increases in total
serum IgE levels associated with continued i.n. HDM installation. Serum was collected from all animals
before the initiation of ASIT (following 2 weeks of HDM exposure; red) and after long-term ASIT (at
sacrifice; blue). Total serum IgE levels were determined via ELISA. Data represent mean ± SEM values;
n = 5 per group. Statistical comparisons were made between groups pre-ASIT as well as post-ASIT. No
statistical differences were observed.
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Figure 29. AHR is not suppressed in mice receiving either high-dose or low-dose ASIT. C57BL/6
females who had undergone (A) long-term ASIT or (B) short-term ASIT were tracheostomized,
mechanically ventilated, and subjected to methacholine challenge. Changes in Rrs responses to increasing
doses of aerosolized methacholine were determined using the flexiVent system (SCIREQ). Data represent
mean ± SEM values; n =5 per group. For statistical purposes, group comparisons were based on area
under the curve (AUC) measurements. No statistical differences were observed.
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Figure 30. Long-term ASIT reduces lung Th2 cells in a dose-dependent manner. Lung leukocytes were
gated on CD3+CD4+ T lymphocytes and T1-ST2 expression was examined to determine the frequency
and number of Th2 cells. Data represent mean ± SEM values; n = 5 per group. *p<0.05 vs. HDM-control.
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Figure 31. Long-term ASIT is not associated with increases in Foxp3+ Tregs or IL-10+ AMs. Vert-x mice
were subjected to i.n. HDM and long-term ASIT as shown in Chapter 2, Fig 5B. (A) Cells were gated on
CD3+CD4+ T lymphocytes and Foxp3 expression was examined. Total percentages of Foxp3+ Tregs were
determined. (B) MFI of IL-10-GFP expression in CD11c+ AMs is shown. Dotted line represents negative
control (GFP- AMs from a WT mouse). Data represent mean ± SEM values; n = 5 per group. No
statistical differences were observed between groups.
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CHAPTER 6
DISCUSSION AND FUTURE DIRECTIONS

Innovation
Herein, we have provided the first evidence that short- to intermediate- term (2 to 5 wks)
intranasal HDM administration promotes development of AAD, while continuous, long-term (11 wks)
HDM instillation results in suppression of AAD. These findings were unexpected given that we had
previously hypothesized that the immunologic complexity of HDM would inhibit the development of
immune tolerance with long-term HDM administration. However, we do believe that this suppressive
phase of disease is truly the result of immunologic tolerance due to the presence of immunosuppressive
leukocytes (IL-10+ AMs, Foxp3+ Tregs) at the inflammation site. Moreover, we have shown that IL-10+
AMs from long-term HDM-exposed animals are capable of inducing Foxp3+ Tregs in vitro, a function
that has never before been demonstrated with allergen-primed AMs. AMs and Tregs likely cooperate to
suppress the features of AAD, although their specific roles in this long-term HDM model have not yet
been teased apart (Fig 32).
Few studies have examined the effects of long-term HDM exposure on the inflammatory
response and even fewer have studied this in the context of tolerance. Thus, this HDM model has
tremendous utility for exploring the mechanisms governing immune regulation against complex
aeroallergens. Continued investigation into this clinically-relevant, biphasic mouse model of AAD may
provide successful approaches for tolerance induction in individuals with asthma.
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Future directions and considerations
While these studies have certainly yielded exciting results, there are many more questions that are
left to explore:

What does suppression of HDM-induced AAD indicate about the pulmonary state of patients without
evidence of AHR?
The HDM-induced AAD model has been extensively utilized among scientists interested in the
mechanisms that promote development of asthma; however, studies in long-term HDM models have been
few and far between. Our laboratory is the first to demonstrate that long-term HDM exposure can
promote a state of immunologic tolerance. However, the suppression of disease that occurs as a
consequence of this tolerance is quite unlike the phenomenon of LIT that we have observed with longterm OVA exposure. Despite the fact that both are associated with elevations in Tregs in the HLN
(suggesting that some form of active tolerance is certainly responsible for both phenotypes), HDMassociated suppression of AAD is marked by persistent perivascular and peribronchiolar mononuclear
lung inflammation, whereas OVA-LIT lungs do not show any evidence of inflammation. Thus, the big
question that remains to be answered from these studies is whether the suppression of AAD responses
(namely eosinophilia and AHR) suggests absence of disease in the presence of residual inflammation or
progression to a different stage or type of lung disease that is no longer signified by a Type I
hypersensitivity response. There are several lines of evidence to suggest that the latter is indeed the case,
including the fact that IgG1 levels become significantly elevated over the course of HDM exposure.
Although not previously discussed, we have also performed histopathologic analysis on lungs from 22
week HDM-exposed mice that demonstrate development of alveolitis in addition to peribronchiolar and
perivascular infiltrates despite continued suppression of AHR (Fig 33). Could this long-term HDM model
signify progression from an asthma-like phenotype to hypersensitivity pneumonitis, two closely related
diseases? The latter is marked by a Type IV hypersensivity reaction in which repeated exposure to antigen
leads to acute mononuclear alveolitis, intersitital lung infiltration, elevated IgG levels and a
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granulomatous-like reaction225, all of which are present following 11 to 22 weeks of continuous, HDM
exposure. The evidence against this theory is the fact that hypersensitivity pneumonitis is associated with
pulmonary fibrosis, which surprisingly is not evident at any stage within this 2-22 week HDM model.
However, fibrosis can be a slow and insidious process and thus may not be evident until HDM exposure
is prolonged for an extreme length of time.
Regardless of whether AAD progresses to hypersensitivity pneumonitis within the context of this
model or not, what is the significance of persistent inflammation within the lungs despite reductions in
Th2 inflammatory patterns? We have speculated that persistent mononuclear inflammation in spite of
attenuated mucus production and AHR may be attributed to the tremendous antigenic complexity of
HDM141,177. It would be valuable to perform additional studies with heat-inactivated HDM to specifically
reduce the activities of LPS and various proteolytic enzymes. If this prevented the persistence of lung
inflammation with tolerance, one may simply credit the discrepancies between our OVA and HDM
models to the fact that these allergens differ so much in their antigenic compositions. However, the
possibility exists that this inflammation is truly representative of the lung status in asthmatic patients who
have regained tolerance through ASIT or other forms of therapy. In this regard, it is intriguing to
speculate that potential subclinical lung inflammation (in the absence of airway eosinophilia,
methacholine AHR, or asthma symptoms) could play a role in the relapse of asthma in 40-50% of
remitted individuals in later adulthood183-185. Yet a second possibility exists that the inflammatory cells
observed in the lungs of tolerant mice are primarily regulatory in nature, despite their concerning
appearance on histopathology. We have supported this theory by demonstrating a regulatory role for AMs
in the lungs of tolerant mice. Follow-up experiments should focus on the functional attributes of other
major cell types (e.g. Teff) in the lungs of tolerant mice to determine whether these cells have the same
potency (e.g. proliferative ability, Th2 cytokine secretion) as those from diseased mice.
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Do AMs truly have a role in tolerance against inhaled allergens?
Although the data presented within this dissertation suggest that AMs do not play an essential
role in tolerance induction, additional studies must be done to conclusively rule this possibility out based
on the fact that our macrophage depletion techniques had some associated limitations (see Chapter 4).
The issues involved with using clodronate liposomes to deplete alveolar macrophages could potentially be
avoided by using CD11c-DTR mice, although this is also not an ideal option because of the added
possibility of simultaneous DC depletion (a fine example of the fact that innate immune technology is not
nearly as developed as that for adaptive immune cells). However, the bigger limitation in our studies was
the fact that IL-10+ AMs were not able to be specifically depleted, thus preventing us from segregating
their potential anti-inflammatory effects among the total AM population. This question may be better
addressed in the future by sorting IL-10+ AMs from tolerant mice and adoptively transferring them
intratracheally into naïve or diseased mice to determine their effects on the kinetics of AAD.
If AMs do play a role in tolerance induction, where does this occur? Previous literature suggests
that the induction of Tregs by AMs is not likely to occur in lymph nodes, as AMs do not migrate to the
HLN in large numbers103. This finding was supported by our in vivo AM depletion studies. However, we
have shown a steady increase in HLN Treg numbers over the course of the model, begging the question of
where these Tregs come from. Based on results from prior studies, Treg induction by AMs can occur in
the lung tissue103. Our data support this finding, as lung AMs were able to induce Tregs in vitro, although
we have not seen an accumulation of Tregs in the lungs of HDM-tolerant mice relative to mice with signs
of AAD. Nevertheless, we have observed that Tregs are certainly being generated in the lungs of HDMtreated mice relative to control animals at all time points. Are Tregs generated in the lungs of HDMexposed mice in vivo, from where they can then migrate to the HLN to dampen Th2 responses? It has
indeed been shown that Tregs can migrate sequentially from inflamed tissues to draining lymph nodes
during an immune response, a movement essential for optimal Treg suppression226. Along these lines, it
would be interesting to intratracheally transfer Tregs from HDM-tolerant mice into congenicallymismatched hosts to determine whether they traffic to the HLN upon HDM sensitization/challenge.
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By what process(es) do AMs convert T cells into Tregs? Our confocal imaging data did not
demonstrate any direct interactions between AMs and CD4+ T cells in the lungs. Moreover, in vitro data
show that AMs from long-term HDM mice are not a major source of TGF-β despite the fact that they are
able to induce more Foxp3+ Tregs than AMs from short-term HDM or time-matched PBS control
animals. Do AMs from HDM-tolerant mice provide a critical soluble mediator that enhances Treg
induction without the need for cell-cell interactions? This possibility should be tested by performing Treg
induction assays using a transwell system to prevent direct AM-Teff contact. Furthermore, might there be
other mechanisms in addition to IL-10 by which these AMs mediate their tolerogenic effects? Retinoic
acid has been shown to increase Tregs by enhancing TGF-β signaling via Smad3 phosphorylation227.
Multiple studies have shown that AMs can induce Tregs in a retinoic acid-dependent manner98,103, and so
additional Treg induction assays should be performed in the presence of retinoic acid inhibitors. However,
this targeted approach may not be the most efficient way to identify critical differences between AMs
from long-term and short-term HDM mice. Next steps for this project should center on performing RNAsequencing analysis of IL-10+ and IL-10- AMs throughout the various stages of the model in order to
cultivate a better understanding of the specific changes occurring within this cell population with
tolerance. Not only would this help identify additional mechanistic targets for tolerance, it may yield
additional phenotypic markers of these cells that would allow us to track their relevance in genetically
modified (i.e. IL-10-/-) mice.

Considerations for ASIT: can we improve upon our current clinical protocols?
Herein, we present the first murine model of HDM-ASIT for the treatment of AAD. This model
has numerous advantages, including a clinically-relevant study design (i.e. initiation of treatment post
development of disease) and utilization of a standardized HDM extract and biweekly dosing schedule
comparable to that administered to asthmatic patients. Moreover, studies from this model can be used to
more accurately describe the clinical effects of subcutaneous ASIT at the site of inflammation, which
cannot easily be accessed in asthmatic subjects.
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Despite the tremendous utility of this model, one of the major concerns with its development has
been poor repeatability of results. It should be noted that the studies presented in Chapter 5 are
representative of the first (and most striking) experiments conducted for both short- and long-term ASIT
studies. Failure of short-term ASIT to show effectiveness after three additional repeats was not surprising,
since it is well known that the clinical benefits of ASIT correlate with duration of therapy228. We thus
adopted the long-term ASIT model in order to improve our odds of observing immunological benefits
with therapy. Our long-term ASIT model showed striking differences during our pilot experiments, with
changes in almost all major components of allergic inflammation including airway leukocyte numbers,
eosinophil levels, IgE levels, lung inflammation, mucus production, and lung Th2 cells. However, when
we attempted to repeat these results an additional time using the same clinical protocol, we did not
observe such strong differences among groups, raising concerns about how robust most ASIT protocols
really are. There is a good deal of evidence to suggest that the benefits of ASIT really do vary from
patient to patient. A 2010 Cochrane review of 88 trials in asthma patients receiving ASIT demonstrated
that although the combined data showed an overall significant improvement in asthma symptom scores,
there was a great deal of heterogeneity among trials across a number of comparisons229. Moreover,
number needed to treat was typically found to be 3-4 depending on the outcome measured, suggesting
that the effects of ASIT a) benefit some but not all patients and b) range dramatically in effectiveness
depending on the patient. Interestingly, this heterogeneity was also reflected within our genetically similar
mice. Thus, while it will certainly be important for us to experiment with different treatment protocols
(e.g. dosage, duration, location, etc.) in the future to find one that is both effective and robust, murine
studies will be limited across the board to understand why certain subjects respond to ASIT while others
do not. Human studies will be of more help in this arena. More effort should be expended to stratify
subjects according to their asthma type and immunologic profile so that these parameters can be directly
correlated with ASIT outcomes in these patients. In addition, more studies are required in humans to
determine the most effective treatment regimen (e.g. dosage, number of injections per week, route of
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injection) for each common allergen, as these protocols can vary drastically from clinical site to clinical
site.
In addition to experimenting with various ASIT protocols, there are several other key
immunologic parameters that have left to be explored in this model. What is the status of HDM-specific
IgE and IgG1 within the serum and within the airways? How does the ratio of Th2 to Th1 cytokines in the
BAL and lung tissue change with ASIT? Is basophil activity altered with ASIT? It is critical that we can
answer these questions using clinically-relevant mouse models, as these compartments are inaccessible in
human subjects. Moreover, cytokine and immunoglobulin status in the serum versus the lung
compartments do not always correlate, and so it is particularly critical that we do not rely solely on our
human data for these answers.
How then does subcutaneous ASIT benefit patients with asthma? Clearly, this mechanism must be
different from those involved in traditional tolerance with inhaled allergen exposure. Our data suggest
that subcutaneous ASIT is able to effectively decrease Th2 cells in the lungs, but do not indicate an
essential role for Foxp3+ Tregs or IL-10+ AMs in its efficacy. Certainly IL-10+Foxp3- Treg status needs to
be examined within our model, as these cells have been implicated in the overall efficacy of ASIT
throughout a number of studies. However, the theme of our data (and of the majority of asthma literature)
suggests multiple cellular mechanisms are likely at play here. Studies have shown that IgG4 blocking
antibody production is confined to IL-10-producing regulatory B cells (Bregs) and that these cells
increase with ASIT in allergic patients230. We have similarly demonstrated in our murine model of OVAinduced AAD that Bregs have a contributory role in tolerance against inhaled allergens152. Thus, the role
of these cells in the lungs should specifically be examined in this long-term HDM-ASIT model. Other
potential cell types to explore within this model include CD8+ T cells and IL-10-producing DCs. We are
also currently in the process of examining whether specific changes in the microbial community within
the gut may play a role in the efficacy of subcutaneous ASIT.
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Concluding remarks

“I am wiser than this man, for neither of us appears to know anything great and good; but he fancies he
knows something, although he knows nothing; whereas I, as I do not know anything, so I do not fancy I
do. In this trifling particular, then, I appear to be wiser than he, because I do not fancy I know what I do
not know.”
-Plato

We exist among a community of researchers that has dedicated itself to identifying a seemingly
endless list of cells and cytokines that contribute to the pathogenesis and regulation of asthma- the
thought being that we can exploit this knowledge to create novel and specific pharmacologic agents for
asthma. Our laboratory has contributed a unique perspective to this issue through the development of two
biphasic AAD models (OVA and HDM) that allow us to study disease progression and resolution over
time. As a community, we have successfully reduced disease in our mouse models time and again by
either blocking pathogenic cells, antibodies, and cytokines or tipping the balance in favor of regulatory
cells. Hundreds of papers have been published in the last decade alone that have yielded promising results
for the field of asthma, several of which have proceeded to clinical trials. Yet our clinical trials have, for
the most part, been largely disappointing. Is this simply a reflection of a failing animal research paradigm
for modeling human disease? There is no denying that mice are not a perfect substitute for humans, but
often times we have no option but to conduct our studies in mice. And frequently, we have found enticing
results that correlate in mice and humans. We know from our studies that IL-10 is secreted in large
amounts by AMs from HDM-tolerant mice and is underproduced in AMs found in asthmatic patients
when compared to healthy controls231. Moreover, randomized, double-blind trials have shown us that
pharmacologic agents capable of reducing clinical symptoms in asthmatic subjects are often linked to
statistically significant increases in IL-10232. This has made IL-10 and IL-10-producing cells extremely
promising targets for the treatment of asthma. Yet when we administered HDM to IL-10-null animals, we
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observed no effect on tolerance induction despite the overwhelming literature in favor of the antiinflammatory role of this cytokine in asthma. What then can we take from these results and why should
we not abandon IL-10 all together in search of a more overt target?
The pathophysiology of allergic asthma is based upon a simple concept but in reality, this disease
is tremendously complex. While the idea of interrogating a single, specific mechanism in order to find the
“magic” cure to a disease is desirable, it is also the major reason why most science does not translate well
in the clinic. For one, our scientific process, although capable of providing important insights about the
basic mechanisms that govern the human body, fails to take into account the fact that no physiologic or
pathologic process exists in isolation: context is important. It is easy to be discouraged by the fact that
knocking out IL-10 has “no” effect in our asthma model despite the overwhelming clinical evidence in its
favor. However, it is often unclear from such focused studies how additional pathways in the broader
system may change in response to alterations in the pathway of interest. In other words, we have no idea
how the body will compensate for the absence of IL-10 when, by design, we only ever isolate a single
variable at a time. This does not mean that IL-10 is unimportant in the context of asthma, but suggests
that IL-10 is only one of several mechanisms aimed at promoting development of immunologic tolerance.
I believe that this is why inhaled corticosteroids have remained the current gold-standard treatment for
long-term asthma management despite their low specificity. Inhaled corticosteroids are broad-spectrum
drugs, and broadly dampening inflammation is the only way to bypass redundancies in the system.
Finding specific molecular targets (cytokines, genes, antibodies, etc.) capable of attenuating disease in
any significant way is tempting but often difficult to execute. It is for this reason that I advocate that more
research be directed towards the field of ASIT, for this etiologic therapy can target multiple parameters of
allergic asthma simultaneously without the side effect profile of corticosteroids. Why else has ASIT been
our only hope for curing asthma over the last 100 years?
As an aspiring physician-scientist, the process of conducting this research on the involvement of
AMs in tolerance against inhaled HDM has provided me with a newfound appreciation for why we have
struggled to create targeted therapeutic agents for asthma. Deciphering the mechanisms behind disease is
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extremely difficult because one must expect many pathways to be involved, several of which may not be
consistent with our neat and tidy paradigms. Thus, I am left to conclude that there are no easy answers to
these issues we strive to understand. However, I will end by stating my belief there is benefit in the
struggle, regardless of whether or not we generate results that are tantalizing, exciting, or even
“publishable”. The hole-in-one is rare and many will never achieve it. One has to hope for this most
desirable of accomplishments but should not give up learning from every missed swing and every lessthan-ideal shot. From that perspective, there is no such thing as a failed experiment. Every bit of data
advances our understanding of disease regardless of whether it provides the solution to the problem.
Nevertheless, we must also accept the limitations of our deeply focused studies because the full picture is
always so much greater than the sum of its parts. I have been humbled by the clinical hurdles that we will
face in curing asthma and many other diseases, as my doctoral experience has opened my eyes to how
very far we have left to go.
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Figures

Figure 32. A synthesis of the present findings. 2-5 weeks of continuous, intranasal (i.n.) HDM exposure
in a previously naïve mouse promotes Th2 and eosinophilic inflammation, resulting in hallmark signs of
AAD. 11 weeks of continuous i.n. HDM administration induces tolerance via development of IL-10+
alveolar macrophages, which can, in turn, augment the generation of Foxp3+ Tregs in the presence of
TGF-β from an unknown source. Tregs and AMs from tolerant mice likely cooperate to suppress features
of AAD.

132

Figure 33. 22 weeks of continuous, intranasal HDM exposure is associated with persistent perivascular,
peribronchiolar lung inflammation and development of mild alveolitis. Formalin-fixed lungs were
processed in a standard manner and stained with H&E (X10). Arrows highlight examples of distended
alveoli that are surrounded by invading leukocytes.
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